Page 1

Vol.9 No.1 | January-February 2017 | New Delhi

CLIN LAB INDIA at the MEDICAL FAIR INDIA 2017

Discover the # 1 PHARMACEUTICAL

MTA2017

STARLED3 NX - Surgical LED Lamp

t n e v e

CPhI Istanbul

to spotlight new TECHNOLOGIES

MeetTheWomenPersonalities

Namrata Purohit

Celebrity fitness instructor

Dimple Mirchandani

Founder – Holistic Nutrition

Suman Agarwal

Celebrity Fitness Trainer


NEW

www.cphi-istanbul.com info@cphi-istanbul.com

21x28 ingilizce ilan adamlÄą.indd 1

Supporters

Diamond Sponsor

Organisation

04/01/17 15:54


e

d

i

t

o

r

i

a

l

h i g h l i g h t s 4 6 9 10 Vol.9 No.1 | January-February 2017 | Annual Suscription: Rs.2,000 | Overseas: US$250

16 20 23 27 29 32 35 39 42 43 44 50 54

CLIN LAB INDIA at the MEDICAL FAIR INDIA 2017 in New Delhi MEDICAL FAIR THAILAND 2017 STARLED3 NX - Surgical LED Lamp CPhI Istanbul hosts government and industry to strengthen Turkey as MENA pharma hub CEMAST-World’s first Centeroffering Courses in 11 specialities for Minimal Access Surgery Celebrity fitness instructor Namrata Purohit MTA2017 to spotlight new technologies with specialised zones Sempermed Builds New Glove Factory in Malaysia Draft Medical Device Rules fall short of the expectations of the medical devices sector BioPharmX Data Suggest Anti-Inflammatory MediWorld - China International Medical Travel Show launches in 2017 as China’s premier health tourism event Genomic Testing to be Harnessed for Precision Medicine Dimple Mirchandani Founder – Holistic Nutrition IIMC 2017 – International Injection Moulding Conference in Aachen Suman Agarwal –Celebrity Nutritionist and Fitness Trainer Farah Khan leads the talk on infertility with Merck’s ‘Parents of Fertility’ initiative Unique Group brings expertise in hyperbaric oxygen treatment chambers to new healthcare markets

Post-Budget Statement from Dr. Vivekanand Jha, Executive Director, The George Institute for Global Health India

W

e welcome the increase in health allocation to Rs. 47,352 crores, an increase of RS 10,000. We do hope this will support increase in essential healthcare delivery with the aim of achieving universal healthcare. However, we also feel that the Union Budget 2016-17 does not provide information on follow up on the reforms announced by the Finance Minister in the budget proposals of the previous year, where he focused on the rising burden of non-communicable diseases especially kidney disease and launched a national dialysis programme. While he has announced the conversion of 1.5 lakh sub-centres into wellness centres, we have to look at the details in terms of how wellness is being defined. The intent to bring new rules regarding medical devices is welcome but

once again the devil would be in the details. It is important that the focus is not solely on technology, but on ensuring integration of devices with the health system. We applaud the digital health village idea, which provides a good opportunity to take an integrated, evidence-informed approach to management of chronic diseases. It would be important to move from slogans to evidence-based implementation plans. We wish there was more in the budget 2016-17 to reassure us that the mismatch between the current and future disease burden, and the health policy has been recognized and will be addressed.

About The George Institute for Global Health: The George Institute for Global Health is improving the lives of millions of people worldwide through innovative health research. Working across a broad health landscape, the Institute conducts clinical, population and health system research aimed at changing health practice and policy worldwide. The Institute has been ranked among the top 10 global institutes for impact for the last several years. The George Institute India partners with over sixty national and international institutions such as the Public Health Foundation of India, the Postgraduate Institute of Medical Education and Research, University of Hyderabad; and affiliations with University of Sydney, Oxford and Peking.

Medical Device ASIA | January-February 2017 | 3


A complete rehab in 24 hrs is now a reality in total knee replacement surgery Fast track total knee replacement to relieve patients

A strong team of two: première of CLIN LAB INDIA at the MEDICAL FAIR INDIA 2017 in New Delhi Anyone wanting to reach the medical engineering market in India – one of the most promising in the world – will find that the MEDICAL FAIR INDIA is an absolute must, as it is a leading trade fair which has been well established for many years now. The trade show takes place year on year, alternating between Mumbai and New Delhi, and the latest event attracted over 10,000 visitors and 500 exhibitors from more than 20 countries. The MEDICAL FAIR INDIA 2017 will be held at the Pragati Exhibition Centre in New Delhi from 6 to 8 April. As before, it is likely to achieve similar figures at a very high level. The attractiveness of the event will be further enhanced by the simultaneous CLIN LAB INDIA.

Out of all patients with the complaint of knee pain, 35% knee replacement patients jump the gun and rest move a step back fearing the aftermath pain of the total knee replacement. The fear that the total knee replacement, long considered a painful, time-consuming affair that warranted bed rest for an extended period of time is now a myth. Medical innovations are changing people’s perspectives on health every day. The fear factor that was rampant before is slowly eroding away, and complex procedures have now become simpler that allows the mobility of the patient within 24 hours of surgery. Here is the case of 65 year old lady Mrs. Parab, a septuagenarian with the complaint of excruciating distress in her knee, was unable to walk short distances, and could barely even stand, was operated by Dr. Vaibhav Kasodekar, a skilled consulting Orthopedic surgeon with Kohinoor hospital who has performed more than 5000 knee replacement surgeries so far. Believe it or not, she began walking on the same day and was soon exercising her new knees on the passive mobilization machine at the hospital. Expressing her gratitude for the intervention and its pain-free nature, she said “I am glad to make this right decision. With the advancement in technology and ease of procedures, I was able to be independent for my daily chores within 24 hours which were just impossible earlier”. Dr. Kasodekar stated that a canal block, a relatively recent development in pain management, as part of the knee replacement procedure also helps minimize post-operative pain. Accurate alignment of the knees is achieved using computer navigation, leaving no room for errors. This fast-track procedure allows the patient to be discharged within 72 hours of surgery and promises speedy and painless recovery. Dr. Kasodekar’s minimally invasive surgery involves reducing cutting of muscles, which helps improve ease of movement after the procedure. Kohinoor Hospital’s dedicated Orthopedics department has pioneered many breakthrough surgeries that have given a new lease of life to people suffering from excruciating knee and hip joint pains. 4 | November-December 2016 | Medical Device ASIA

Celebrating its première, CLIN LAB INDIA will be an integral part of the programme at MEDICAL FAIR INDIA – a conference accompanied by an exhibition (in Hall 9) and organised by Scherago International in collaboration with the Messe Düsseldorf Group. Well-known speakers from science, clinical practice and business will give talks on current trends in medical laboratory research. They will include James H. Nichols, Professor of Pathology, Microbiology and Immunology at Vanderbilt University in Nashville (USA). The main emphasis will be on point-of-care testing, molecular diagnostics and clinical chemistry. The exhibition space at CLIN LAB INDIA will be occupied, among others, by companies such as Mindray, Randox and SMC Pneumatics. One major international growth market is considered to be in-vitro diagnostics applications, estimated to comprise a global volume of nearly $60 billion. (Source: Boston Biomedical Consultants and Verband der Diagnostica-Industrie Deutschland). Where topics are concerned, the MEDICAL FAIR INDIA (in Halls 8, 9, 10, 11, 12 and 12a) will feature not only medical laboratories, but also medical devices and engineering, technology, equipment and furnishings for hospitals and health centres as well as mobile health solutions and health IT, two areas which are currently attracting considerable attention throughout the world. The main target group will be decision-makers in the medical field (e.g. doctors and healthcare professionals) as well as senior management at hospitals. However, it should also be of interest to architects, building planners, management consultants and those in research and development, as was impressively confirmed by the steady increase in visitors over the past few years. The last event alone attracted over 10,000 visitors in all. Further details about MEDICAL FAIR INDIA 2017 can be found on the web: http://www.medicalfair-india.com. About MEDICAL FAIR INDIA MEDICAL FAIR INDIA is a trade fair in the product family World of MEDICA. It is held by Messe Düsseldorf India, a subsidiary of Messe Düsseldorf, and takes place in close cooperation with the team of Düsseldorf’s leading global trade fair MEDICA. All the facts, figures and information on World of MEDICA trade fairs are available online at http://www.world-of-medica.com.


MEDICAL FAIR THAILAND 2017 The 8th edition of MEDICAL FAIR THAILAND, the leading medical and healthcare event in Thailand and the region, will take place at the Queen Sirikit National Convention Centre (QSNCC) in Bangkok, Thailand from 6 – 8 September 2017.

S

ince its inception in 2003, MEDICAL FAIR THAILAND has grown in size, stature and is recognised as Thailand’s most important resource and business platform for both international and regional suppliers from the medical and healthcare sectors. In 2015, MEDICAL FAIR THAILAND held its largest edition to date as it welcomed 600 exhibitors from 42 countries including 15 national pavilions and country groups from Austria, Belgium, China, France, Germany, Japan, Malaysia, Singapore, South Korea, Taiwan, Thailand, UK and for the first time the USA, Turkey and Italy. The testament to the exhibition’s success was further reflected in the number of visitors, as the 7th edition welcomed 7,226 quality trade

buyers and decision makers from mainly Thailand and the ASEAN region. Focused on equipment and supplies for the hospital, diagnostic, pharmaceutical, medical and rehabilitation sectors, MEDICAL FAIR THAILAND 2017 will once again bring together new and innovative technologies, solutions, products and services from around the world. In its upcoming edition, the exhibition will emphasise on Connected Healthcare and Geriatric Rehabilitative Care across two dedicated platforms and numerous concurrently held events. For one, the Connected Healthcare platform aims to demonstrate innovative digital solutions such as wearables that are transforming the understanding of patient’s health statuses, improve care and deliver greater results. At the same time, and returning for its 3rd edition, the Advanced

6 | January-February 2017 | Medical Device ASIA

Rehab Technology Conference (ARTeC) will focus on innovative and effective technological solutions to decrease mobility related disabilities. Co-organised by the Thai Rehabilitation Medicine Association, the Royal College of Physiatrists of Thailand and Messe Düsseldorf Asia, the academic conference will welcome international key thought leaders to share insights on robotic transfer systems, robotic arm training devices, robotic gait training and wearable devices. Serving as a converging point for healthcare providers, medical suppliers, industry professionals, government bodies, hospital administrators, doctors, nurses and other healthcare professionals sourcing for the latest innovations in medical and healthcare, MEDICAL FAIR THAILAND 2017 is expected to draw 700 exhibitors, 17 national pavilions and country groups and 8,500 quality trade visitors. Bookings for exhibitor spaces are now open and exhibitors are urged to secure their booth space early. More information on MEDICAL FAIR THAILAND 2017 can be found at www.medicalfairthailand.com About Messe Düsseldorf Asia Messe Düsseldorf Asia is a subsidiary of Messe Düsseldorf in Germany, one of the world’s leading trade fair organisers, responsible for organising more than 20 global No. 1 exhibitions in various industries including medicine and health, specifically MEDICA, COMPAMED and REHACARE INTERNATIONAL held in Düsseldorf, Germany. With extensive expertise in organising trade fairs in Southeast Asia, Messe Düsseldorf Asia has developed a portfolio of numerous trade fairs in the region since 1995. For more information, please visit mda.messe-dusseldorf.com For more information on the exhibition, please contact: Daphne Yeo Senior Project Tel: (65) 6332 9682 Tmedicalfair-asia@mda.com.sg`


Baldwin creates global UV curing

powerhouse by acquiring Air Motion Systems

Top players in UV and LED unite to form the world’s largest provider of energy-efficient curing solutions and development, engineering, manufacturing capacity and service to meet their growing needs in the market,” said Pat Keogh, one of the commercial leaders of AMS SPECTRAL UV. “We are proud to continue to offer innovative solutions in a new world being driven by the rapid advancement in UV and LED curing technologies.”

Two major players in the UV curing systems industry, Air Motion Systems, Inc. (AMS) and Baldwin Technology Company, Inc., are merging their expertise to create the premier provider of UV and LED curing technology across the globe.

B

aldwin, the world leader in highly reactive UV, LED UV and IR drying systems, has acquired Air Motion Systems, the world’s leading provider of LED UV curing technology for the graphic arts industry, expanding its position as the number one customer choice within the market. The new entity of Baldwin, part of the $2+ billion Barry-Wehmiller family of companies, will rebrand as AMS SPECTRAL UV and combine AMS with Baldwin’s UV division. AMS SPECTRAL UV locations will continue to grow their operations in River Falls, Wisconsin; Easton, Pennsylvania; and Slough, U.K. “This acquisition marks the beginning of a new era in providing highperformance solutions for the UV industry,” said AMS SPECTRAL UV President Steve Metcalf. “We’re bringing the top industry minds, technology and experience together to tap an unprecedented opportunity in LED and UV, and to serve an ever-widening range of markets and applications.” The AMS LED UV product portfolio has become the de-facto standard for LED curing in sheetfed offset printing and flexo packaging, with an installed base nearly 10 times that of its nearest competitor. Complementing this technology, Baldwin’s UV division has vast experience in highly reactive UV curing and numerous LED applications outside of traditional print markets. Further, the new curing-technology entity will leverage a massive base of experience serving OEM and industrial markets. “What AMS SPECTRAL UV will provide customers is a doubling of research 8 | January-February 2017 | Medical Device ASIA

According to market intelligence provider Yole Development, the total value of the UV LED market worldwide is projected to grow to US$1 billion-plus in the next five years. AMS SPECTRAL UV aims to capture a large share of the anticipated market by leveraging the scale and resources of Baldwin which, through its

global footprint, supplies processautomation equipment and related consumables, parts and services for the print, film, corrugated, textile and paper and packaging industries. “The establishment of AMS SPECTRAL UV strengthens our ability to provide value to our existing customers while remaining responsive to emerging market opportunities,” said Brent Becker, CEO of Baldwin. “This exciting investment underscores our commitment to a strategy that blends organic and acquisition growth to enhance our global footprint and the technology we can deliver to our customers.”

ABOUT BALDWIN TECHNOLOGY COMPANY, INC. Baldwin Technology Company Inc. is a leading global manufacturer and supplier of process-automation equipment and related consumables for the printing, packaging and other industrial segments, including technical textiles, chip and fiberboard, and film extrusion. Through our global footprint, Baldwin offers our customers a broad range of market-leading technologies, products and systems that enhance the quality of industrial-produced products, with a focus on improving the economic and environmental efficiency of the production process. As a total solutions provider, Baldwin not only offers new equipment to our customers, but also dedicates extensive resources to maintaining and servicing existing equipment. Baldwin is privately owned by Forsyth Capital Investors, a Barry-Wehmiller Group company. For more, go to baldwintech.com. ABOUT BARRY-WEHMILLER Barry-Wehmiller is a diversified global supplier of engineering consulting and manufacturing technology for the packaging, corrugating, sheeting and paper converting industries. By blending people-centric leadership with disciplined operational strategies and purpose-driven growth, Barry-Wehmiller has become a $2+ billion organization with 11,000-plus team members united by a common belief: to use the power of business to build a better world. CEO Bob Chapman shares the story of the company’s transformation in his new book, Everybody Matters: The Extraordinary Power of Caring for Your People Like Family. To learn more, go to barrywehmiller.com.


STARLED3 NX - Surgical LED Lamp

STARLED3 NX is on the Next light, long life and for countless room. It is ideal dermatology, general

a lamp manufactured by ACEM based generation LED technology, assuring cold low energy consumption. The lamp is suitable applications both for surgery and operating for diagnosis, dental sector, gynecology, medicine and surgery.

STARLED3 NX light thanks to its Company that directs

grants a homogeneous and shadowless special LED optics created by ACEM Medical light beams at best according to the needs.

The visual area is visual comfort and LEDs produce an temperature (CCT) of of 95.

perfectly illuminated assuring both excellent working conditions. Its next generation unparalleled quality of light with a colour 4.500 °K and a colour rendering index (CRI)

STARLED3 lux with 69W. The hours.

NX has a light intensity of 130.000 a low energy consumption of

life

cycle of its LEDs is about 50.000

STARLED3 NX is composed by three reflectors that produce a wellblended and intense cone of light focusable through the automatic adjustment of the light spot diameter. Its slim, practical and compact design makes it perfect for several uses. The lamp is ergonomic, easy to move and to position and suitable for the laminar flows of the operating room. Its ENDO function (light for endoscopy) gives the possibility to use STARLED3 NX for minimal-invasive surgery too. The easy -to-clean shape and material of STARLED3 NX as well as its removable, sterilizable and easy-to-grip handle assure an excellent cleanliness.

Functions are adjusted by its innovative easy-to-read, ergonomic and easy-to-clean I-SENSE® control panel. With a simple touch it can manage easily and accurately: • ON/OFF function • Light intensity adjustment • DoF - Depth of Field for a deep light • ENDO - Light for endoscopy ideal for minimal-invasive surgery • SIZE - Light spot diameter adjustment to focus the operating area • SYNC - Function (optional) useful to synchronize controls of the combined lamps: STARLED3 NX double (twin dome configuration) and STARLED3 NX together with STARLED5 NX or STARLED7 NX. STARLED3 NX is available in the following versions: Ceiling mounted, (Single, double configuration or together with other STARLED NX lamps) , Wall mounted, Trolley mounted ( ABPS battery on demand) . ABPS is a rechargeable battery powered system made by ACEM Medical Company dedicated to power surgical lamps as by European Directive 93/42/EEC. STARLED3 NX with ABPS has the same performance and appearance, since the structure containing the battery is within the trolley base. The structure which covers and protects the battery is made of resistant plastic, and its dimensions are: 550 x 340 x 240 mm. The control panel on the structure allows managing all fundamental parameters, such as residual charge, type of power supply, recharge status and electrical power supply presence, amongst others. ABPS: • has an electronic control which allows for automatic switch from electric power supply to battery power supply so that STARLED3 NXcan be used as a high performance mobile unit. • is recharged by an automatic charger and requires no specific maintenance. Its autonomy may vary depending on the battery model, which can be from 12 Ah to 28 Ah with maximum charging time of about 8 hours. Acem S.p.A., Medical Company Division, Via della Tecnica 29 40050 Argelato - Bologna – ITALY , Phone + 39 051 721844 Email: info@acem.it, Website: www.acem.it Medical Device ASIA | January-February 2017 | 9


CPhI Istanbul hosts government and industry to strengthen Turkey as MENA pharma hub CPhI Istanbul 2017 is an international event where the pharma professionals can discover the number one pharmaceutical event in the MENA region

For the fourth consecutive year, Istanbul will host the most important pharma gathering in the region for you to meet suppliers, as well as to build new partnerships and gather insight on the market. CPhI Istanbul, and its co-located events, bring together local Turkish and regional drug manufacturers with global suppliers of raw materials, machinery, packaging solutions and contract services. The event gathers over 200 exhibitors and attracts more than 4,000 attendees from the region looking for suppliers and manufacturing partners to bring costcompetitive pharmaceuticals to their individual markets. This year’s expo will give you access to the entire pharmaceutical supply 10 | January-February 2017 | Medical Device ASIA

chain via these co-located shows: CPhI: for pharmaceutical ingredients ICSE: for contract manufacturing and services P-MEC: for pharmaceutical machinery, technology and equipment InnoPack: for pharmaceutical packaging and drug delivery systems The show is heavily supported by the Ministry of Health (Turkish Medicines and Medical Devices Agency) and the Pharmaceutical Manufacturers Association of Turkey (IEIS) – highlighting the integral role it is playing in stimulating regional growth. In total, the event is forecasted to attract over 4,200 attendees and over 200 exhibitors, with attendance from regional heavyweights such as DEVA, BD, Koçak Farma…


Turkey is already established as the regional pharmaceutical hub, and having experienced the fastest growth rate in the OECD – averaging 6.7% per year from 2011-2018 – it is positioned to emerge as a top ten global healthcare economy by 2023. Key to this transformation is CPhI Istanbul, which will run a high level conference in parallel to the exhibition – specifically designed to provide vital market information, key growth opportunities, and create new strategic alliances to ensure future business success. The Turkish pharma market has an end-user spend of US $9.1 billion and is already the seventh largest in Europe, with around 80 production facilities, 20,000 employees and direct access to the pharma markets of the Middle East and North Africa. As a result, CPhI Istanbul has seen rapid growth and has cemented its role as the key event for pharmaceutical solution suppliers from across Turkey, the Balkans, the Middle East

and North Africa, and South East Europe. Another factor contributing to rising international interest is that the Turkish pharma market still relies heavily on imports, representing 50% of the total industry output. However, a critical consideration for international suppliers looking at market entry is access to robust business intelligence to inform better decisions about the right opportunities to pursue. CPhI Istanbul is helping disseminate this market knowledge through its Bio conference (a paid conference). The inaugural Bio Conference Istanbul 2017 is the ‘Bio-Leaders’ Destination’! A three days Conference and Exhibition taking place alongside CPhI Istanbul Exhibition and covering the latest trends and developments in Biologics, Biosimilars and Biobetters. With support from the local government, the Bio Conference is the only event in the region to deliver critical insights needed to navigate the

evolving regulatory, strategic and technical landscape on this rapidly developing market. The program includes a series of thought provoking presentations, interactive panel discussions and dedicated networking opportunities, helping the delegates to understand this complex and exciting market.

Other highlights at CPhI Istanbul 2017 include: • For the second time, CPhI’s eponymous Matchmaking Programme comes to Istanbul –complimentary to all attendees – this programme provides the opportunity to actively target the companies that best match individual business needs. It includes a dedicated area solely designated to hosting meetings and allows attendees to pre-plan their schedules and make the most productive use of business opportunities. • CPhI Istanbul is also a part of the Hosted Buyers Programme from the Turkish Ministry of Economy, which allows

for the costs of eligible buyers to be covered by the Turkish Government. • C-Summit, supported by Fortune Turkey Magazine, gathers the leading CEO’s in the Pharma industry to discuss key issues in the market. This high level summit will take place on the show floor, with discussions centered on how to establish long-term partnerships in Eurasia, market advantages and limitations, as well as the road map for next five years in the region. • Finally, the Women’s Networking Breakfast will feature a panel discussion on “Breaking the Glass Ceiling” and is designed to support networking and further empower female executives as business leaders in pharma. • Gala Night: This is a great networking event for all pharma professionals. During the gala event, the awards of 2017 will be presented. To register online and learn more about CPhI Istanbul visit: http://www.cphi.com/istanbul/

Medical Device ASIA | January-February 2017 | 11


Tyromotion unveils its Virtual Reality vision for robotic rehabilitation • • • •

DIEGO - robotic arm rehabilitation - in combination with Virtual Reality. Robotics and Virtual Reality for faster stroke recovery. Revised PABLO system - hand-arm rehabilitation - with new wireless and cognitive features. First time presentation of virtual high-end rehabilitation room. Complete innovative TYROSOLUTION concept available for testing and consulting.

Tyromotion, a world leader in rehabilitation technology has developed a novel rehabilitation device combining robotics and Virtual Reality for faster stroke recovery. Using Virtual Reality glasses and a

bilateral 3D arm robot the patient emerges completely in a virtual world in which next to the visual also the physical environment can be shaped. This helps patients with limited arm function to perform exercises of daily living and to increase range of motion and repetition during training, both essential to motor learning. “The virtual reality component helps us

to create a 3-dimensional training environment, which can be tailored exactly to the abilities of the patient and is extremely motivating due to the serious gaming component.” says Dr. Alexander Kollreider, CTO of Tyromotion. DIEGO was shown in combination with Virtual Reality at

can truly change the way we do therapy today. We will soon find virtual reality glasses in every living room and that should be the way to deliver motivating and cost effective therapy to everyone. Our new device is the first step into this near future.” adds David Ram, CEO

for the first time its virtual highend rehabilitation room which can be accessed via a Virtual Reality headset. This virtual room conveyed in a memorable way to the fair-visitor how day-to-day therapy, aided by robotic- and computer based devices, looks like.

last year’s MEDICA.

of Tyromotion.

The company plans to introduce this new technology as soon as possible into the market so every patient suffering from a stroke can benefit from this new way of treatment. “Given the initial response from doctors and therapists we are confident that this novel approach

At Medica last year, Tyromotion also presented its revised PABLO system. New wireless and cognitive features are added. The PABLO system is one the most successful products within the TYROMOTION portfolio.

Additionally, the user perceives the advantages by using the innovative TYROSOLUTION concept compared to conventional therapy solutions. The whole TYROSOLUTION concept was exhibited and fair visitors had the possibility to test the devices by themselves as well as got professional consulting from Tyromotion employees.

Tyromotion additionally presents

Medical Device ASIA | January-February 2017 | 13


Voxtur Bio enters the export market With everything geared up, the firm has started exporting to 16 countries much more is in the agenda for tapping the export potentials,” Khushroo said.

Changing Trends Regarding the changing trends in the diagnostic segment, Viral said that those days when the treatment was given by doctors in India on the basis of their own prejudgements are over.

T

he Mumbai-based company Voxtur Bio Ltd, manufacturer of invitro diagnostic kits and reagents, has started exploring the export market, with exports to 16 countries that include Angola, Burundi, Cameroon, Kenya, Tanzania, Bolivia, Bangladesh, Qatar, Myanmar, Portugal, Malaysia, Romania, Lithuania, Dubai, Mali and Ukraine. With a full-fledged manufacturing infrastructure in place, the firm has set out an export-oriented growth strategy. Product registrations with the respective ministries of health around the globe are in process and export has picked up well, said Khushroo A. Pastakia, CEO & Executive Director, Voxtur Bio Ltd. “Apart from offering our products under our brand, we have also tied up with couple of world-renowned manufacturing companies for manufacturing our products in their brands, under OEM. This will also provide us an easy way to utilize our manufacturing capacity, to reach out each and every corners of India and abroad,” said Mr. Viral Gandhi, Chairman & Managing Director. Having a wide level of international exposures in more than 100 countries across the world, Khushroo Pastakia has already gained a strong foothold within a very short time frame, in tapping 29 countries, which includes those countries where product registrations are in progress, along with those countries where export have already begun. Voxtur has also undertaken its ground work, with initial participations in international events like Medica in Dusseldorf (Germany) and Arabhealth in Dubai (UAE). Next target for export would be countries such as Chile, Egypt, Ethiopia, Ecuador, Colombia, Moldova, Brazil, the Philippines, Indonesia, Cambodia, Sri Lanka, Thailand and Vietnam, where the product registrations are in progress and expected to be completed couple of months down the line. The company is betting big on the potential in these countries for the rapid test kit market, added Khushroo A. Pastakia, CEO & Executive Director.

Potential of IVD Voxtur will also be concentrating the IVD products market, whose worldwide potential is huge. “Deployment of sales team based on continental structures, participation in major international exhibitions in Europe, Latin America, Middle East and Far East, participation in local exhibitions in selected countries of Africa, product promotion advertisements in selected international media and 14 | January-February 2017 | Medical Device ASIA

“Awareness of cost-effective diagnostic testing tools, before imparting any treatment, created a revolutionary impact over the last one decade. Medical science has provided revolutionary diagnostic tools and techniques to diagnose the diseases in most affordable way, so that right treatment can be given to a patient at right time. The country and its healthcare system are confronted by challenges shared by the developing countries, as well as rising rates of diabetes, cardiovascular disease, and the diseases of aging. Recently, there is a remarkable growth seen in the healthcare awareness and desire to undergo preventive health check-ups that has boosted the IVD industry growth,” Khushroo said.

Quality control Voxtur vouches for quality control which is the key to ensure deliverance of quality products in the international markets. “All our IVD test products must meet the essential quality control requirements that include quality control samplings of incoming, in-process and finished products. Starting from the raw material, to inprocess phase, to the final finished products getting packed, each and every phase of online production is under the constant quality control vigilance. A well-defined system for managing the process of manufacturing is established, as the products at all stages of processing meet the specified requirements as defined in the product Master

Formula Record. Furthermore, controls are also ensured in the work environment parameters that should match the specified requirements. Stage inspections are carried out by quality control personnel at appropriate stages, to ensure the delivery of a world-class product.” Khushroo A. Pastakia is also bullish about the fast-growing diagnostic market in India. “With a population of more than 1 billion, India is the world’s second largest country and therefore also a significant potential market for healthcare. The Indian IVD market stands just next to that of the US, China and Japan and it leads all the emerging nations. The current Indian IVD market is valued at around USD. 500 million, with an annual growth rate ranging around 20% per annum,” he concluded. About Voxtur Bio Ltd. Voxtur Bio Ltd. is a FDA-licensed, GMP-, ISO 9001:2008- and ISO 13485:2003-accredited company, possessing state-of-the-art manufacturing facilities, producing CE-marked Clinical Laboratory Diagnostic Testing Kits. Emphasis on in-house R&D has led Voxtur Bio in developing the most advanced and sophisticated technologies, for delivering high-quality diagnostic testing solutions in the space of in-vitro diagnostic tests. Voxtur Bio has come up with distinctively enhanced IVD products to serve its end users, distributors and manufacturers (on OEM) around the globe. Ensuring highest levels of sensitivity and specificity, each of its product is put through several stringent quality control protocols, that assists its end-users to deliver desired results. Diagnosis being a pre-requisite for undertaking any medical treatment, Voxtur Bio is committed to saving lives of millions around the globe; by ensuring timely, affordable, accurate and innovative diagnosis. http://voxturbio.com


BABY’S CASTLE - India’s first and only Baby and Mother Wellness Centre Launched In Mumbai Baby Castle’s Highlights • First ever baby and mother care centre in India • Registered with Freds Swim Academy (Australia) • Hygienic and completely safe setup • Excellent services for mothers, babies as well as special needs children • Added exclusive features that make it a onestop baby fun zone

I

ndia’s first and only Baby and Mother Wellness Centre - Baby’s Castle was launched in the city of Bangalore, recently. A unique first-of-itskind center in India, Baby’s Castle caters to nurturing, enhancing and advancing the milestones every baby and mother would need to cover in the early stages of childhood and pregnancy, respectively. Registered with Freds Swim Academy (Australia), the services offered at Baby’s Castle not only helps cognitive development in new-borns and infants but also equally focuses on mothers through the first year of motherhood with their luxury Ante-Natal & Post-Natal care. Baby’s Castle aims to be a part of the beautiful journey of motherhood by treating every baby like a precious little star, just as exceptionally cherished by a mother. They wish to be a part of those first beautiful moments of infancy, where every smile, every touch is ultra-gentle and unmatched. Speaking on the launch, Dr Priyanka Bhoir – Founder and Managing Director, Baby’s Castle said, “Child care in the formative years is the most important aspect in any parent’s life. Every parent wants to give the best to their child’s growth. We are glad that with the launch of Baby’s Castle we are going the extra mile by offering and designing an array of ultra-luxurious services for babies & their mothers. Keeping in mind the priceless and pure characteristics of childhood, we have put in our unmatched effort to carefully nurture the little clients that visit our centre and we are confident of making a constructive difference to their growth in the long run.” With an array of best quality products used, Baby’s Castle provides its clients the option to choose from a variety of certified products & find the most beneficial ones for their baby. All the products are chemical free

and meet the standards of certification from AAP (American Association of Paediatric). Some of the baby products have organic certifications from USDA / follow the NSF/ANSI 305 Standard and are appropriately labelled on the products.

About Baby’s Castle Baby’s Castle, India’s first and only Baby and Mother Wellness Centre, registered with Freds Swim Academy (Australia) is a unique first-ofits-kind centre in India, spread over 4141 sq.ft. Baby’s Castle caters to nurturing, enhancing and advancing the milestones and cognitive development in new-borns and infants. Baby’s Castle aims to endow Expecting Mothers, New-Born & Infants with essential “Health Wellness Therapies”, by blending traditional & contemporary practices to nurture & enrich the mother-baby bonding under the guidance of experts in a luxurious and ideal environment. The services provided at Baby’s Castle for babies exclusively focus on Aqua fitness and Aqua comfort which broadly includes Active Spa Therapy, Splash For Toddlers, Infant Spa, creative movement and Zumba. For Mother’s the services include pregnancy Spa, post-partum Spa, Zumba and Pre and Post- Natal Fitness classes. In addition, Baby’s Castle has associated with Dr. C.G Prashant, India’s leading Aqua Physiotherapist for his expert guidance and consultation to clients on need basis. All the services are conducted by trained experts who have Medical Certification in their respective field. Medical Device ASIA | January-February 2017 | 15


CEMAST-World’s first Centeroffering Courses in 11 specialities for Minimal Access Surgery

(L-R): Dr. Mrs Sybill Storz, Chairperson; Karl Storz, Germany; Karl Christian Storz; Prof. Tehemton Udwadia, Chairman; CEMAST & Alfred Cuschieri

As India braces up to be the healthcare capital of the world over the next one decade, CEMAST set the tone and tenor as the World’s first Center offering training in 11 specialities for Minimal Access Surgery. All other Centers across the World offer training in two or three specialities only. The 11 specialities, being offered at CEMAST include General Surgery, Gynaecology, Urology, Paediatric Surgery, Flexible Endoscopy, Bariatric Surgery, ESS, Bronchoscopy, ENT, VAAFT and Knee Arthroscopy. Come 2017, CEMAST plans to add another nine specialities to the existing eleven and those include Endospine Surgery, Neurosurgery, Thoracoscopy, advanced ENT, Difficult Airway, Shoulder Arthroscopy, VATS, Colorectal Surgery and Hepatobiliary Surgery. Doing the honours for CEMAST for the inauguration of their sprawling new Center was Piyush Goyal-Honourable Minister of State for Power, Govt Of India and a host of other dignitaries that included Dr. Mrs. Sybill Storz-Chairperson, Karl Storz GMbh& Co. KG, Tuttlingen, Germany, Mr. Karl Christian Storz and Professor Sir Alfred Cushieri and Prof. Tehemton E. Udwadia-Chairman, CEMAST. Piyush Goyal was lavish in his praise of the state-of-the-art centre and the philanthropic initiatives of Prof. Tehementon Udwadia . Mrs. Sybill Storz expressed immense satisafction and appreciation of the rapid strides made by ceMAST in their 4 years of existence. Karl Christian Storz was at his humourous best with rib tickling anecdotes inspired from his hometown as he waxed eloquent about the humble beginnings of the Karl Storz company . Professor Sir Alfred Cusheri drew sharp attention to the nuances and intricacies of Minimal Access Surgery and enlightened the audience on it’s evolution over the years. Reputed Surgeons and Doctors from every nook and corner of the country were in attendance at this glittering gathering . The Center of Excellence for Minimal Access Surgery Training(CEMAST) has been set up through an altruistic Educationalgrant from KARL STORZ GmbH &Co. 16 | January-February 2017 | Medical Device ASIA

KG, Tuttlingen, Germany, through the involvement of Dr. Mrs. Sybill Storz in humanitarian and educational aid to India. This Center was started in a modest way in Mahalaxmi in 2012 and in 4 years has trained well over 4000 surgeons from all over India, many from rural areas, a 1000 nurses working in Operation Rooms throughout the country, 250 surgeons in Flexible Upper and Lower GI Endoscopy and 150 Pulmonologists, Anaesthetists , Intensivists and Thoracic surgeons in Bronchoscopy. Starting with imparting training in three surgical specialities, this Center today covers 11 surgical specialties, the only Training Center in the world to have this wide diversity, as also this involvement in training the entire MAS team - surgeon, nurse, biotechnician, sterilization team. Due to increased participant demand, and the thrust to start more specialty courses, this Center, with the prompting of Dr Mrs Sybill Storz , has now moved to much bigger premises, three times its former size, with more than double the trainer work stations. The equipment in the new ceMAST is the ultimate in advance and sophistication, perhaps better than that available in most hospitals. The strength of the Center however goes beyond its size, diversity of specialty courses, and equipment. The strength of CEMAST is in its people –

the ceMAST team, who unite to labour extended hours and exult in whatever they do. The Course Directors and the Faculty are drawn from all over India, not only for their expertise, but for their ethics and love of teaching. The participants, who are the raison d’etre of CEMAST’s existence have come from all over India and beyond and have to take an exam and give a feedback which can improve the training. Their eagerness, keenness, total involvement and passion, the intensity in their eye, it is they who give CEMAST the stimulus to excel. The icing on the cake is the Director, whose imagination; ingenuity and innovation create training models of varied complexity, which have made CEMAST the only one of its kind Training Center anywhere in the world. Unlike most courses, where participants leave and are forgotten, CEMAST maintains contact with every participant via an umbilical cord of attachment. The Alumni concept, outreach program, distance learning program, and the planned Mentorship program, all ensure that CEMAST participants remain bonded, not only as CEMAST alumni, but as CEMAST family. Welcome to a great new chapter in medical history, welcome to CEMAST !!


THOMAS 2380 Versatile Pressure/Vacuum Pump

Japan: Shiko +81 90 8051 5394

shiko.iwai@gardnerdenver.com | China: Mark +86-135-0170-935

eddie.lee@gardnerdenver.com

michelle.wu@gardnerdenver.com mark.lou@gardnerdenver.com

keri.mcneill@gardnerdenver.com | Korea: Eddie +82 10 7720 2584

manoj.ahire@gardnerdenver.com | SE Asia: Michelle +852 9170 0693

Australia: Keri +61 (0) 402 275 962

India: Manoj +91 9004282345

B/404, 4th Floor , Kedarnath, opp. Gokulanand Hotel,Western Express Highway, Dahisar (E) Mumbai – 400 068. T: +91 22 658 12345 | F: +91 22 289 20224

Gardner Denver Engineered Products India Pvt. Ltd

provides long-life reliability with low vibration and quiet operation.

x 6.73” (171 mm) high. Its compact design, makes it ideal for use in various applications, while the twin-cylinder design

and has a one-piece monolithic head. Weighing 12 pounds, the 2380 is 9.31” (236.5 mm) long x 5.14” (130.6 mm) wide

The 2380 provides 100 psi (6.9 bar) max pressure with open flow of 2.3 cfm (65 l/min). The new 2380 series is fan-cooled

including medical, dental, industrial packaging/printing, and environmental in pond aeration.

The 2380 series air compressors are designed for pressure/vacuum and high flow, with suitability for a range of applications

New Platform, Large Twin-Cylinder Pump with WOB-L® Technology

THOMAS 2380 VERSATILE PRESSURE/VACUUM PUMP


Indian Celebrity Dia Mirza joins Save the Children as Artist Ambassador

A

ctor, Producer, Director, former Miss Asia Pacific and Humanitarian, Dia Mirza has joined hands with Save the Children; on her birthday, 9th December as an Artist Ambassador. A celebrated personality with the winning combination of beauty with brains, Dia has appeared in several successful films, including the blockbuster Munnabhai series, Parineeta. Dia’s footprints though go way beyond film. A Swachh Bharat ambassador, she is a highly active and effective voice on many social causes, most notably nature conservation and children’s welfare. Dia Mirza is committing to help raise awareness about malnutrition, quality education, gender equality and child trafficking. She will use the reach of her celebrity to champion the rights of children in India and around the world. On this day she also made an impassioned appeal in a video message to create an unstoppable movement for change. “I firmly believe that every person is born to make a difference. And I am thrilled to associate myself with Save the Children – the leading NGO for children; that is truly creating a big change in the areas of education, health, protection and humanitarian needs. My aim is to draw more attention to the organisation’s work so that greater support from government, corporate entities and individuals can be mobilized to benefit the most marginalised children.” said Dia Mirza, Artist Ambassador,Save the Children. Despite ratifying the United Nations Convention on the Rights of the Child 24 years ago, 1.2 million children are still struggling to survive till their 5th 18 | January-February 2017 | Medical Device ASIA

birthday, 84 million have never been to school and 7.8 million are still engaged in child labour. Dia Mirza’s association with Save the Children will go a long way in amplifying the voices of the most poor and excluded children. This is the moment for children to voice their call to action. “We welcome Dia Mirza as an ambassador to Save the Children family. This association will go a long way in amplifying the voices of children. Public figures like Dia Mirza play a significant role in our effort to bring rights of children on top of the public agenda. They are respected influencers and what they say through their work can change perceptions to lead the way to a better country for all children.” said Thomas Chandy, CEO, Save the Children Dia strongly believes that every child has innate rights which need to be protected in all situations. She believes that we must listen to children and let them be our guide to a more sustainable future in which inequalities are reduced, extreme poverty is eliminated and addressing climate change through disaster risk reduction. Every child has the right to survive and thrive, right to play, right to quality education and right to live free of any violence. Children are the change makers for the future, adequate healthcare, nutrition and quality education are the solution to ending the vicious cycle of generational poverty. Save the Children works across 20 states of India; it focusses on issues related to education, health and protection of children, humanitarian work especially for the most deprived and marginalized children.


Dolomite’s Fluidic Factory recognized with R&D 100 Award and the editors of R&D Magazine, who this year recognized the significant contribution the Fluidic Factory is making to the fast growing field of microfluidics. Its success highlights the potential of this system to further research and development in areas such as medical diagnostics, drug development, chemical synthesis, enzymatic bioconversion, biomedical assays and education. Mark Gilligan, CEO of Blacktrace Holdings, commented: “The entire Blacktrace Group is delighted that we have once again been successful at the esteemed R&D 100 Awards, highlighting our strengths in innovation and developing novel technologies with real world applications. This award recognizes how the Fluidic Factory is helping to push the boundaries of microfluidics, enabling faster and more cost-effective prototyping and opening up new avenues of research.” For more information, please visit www.dolomite-microfluidics.com/ webshop/fluidic_factory

About Dolomite

D

oomite, a world leader in microfluidics innovation, is celebrating the success of its Fluidic Factory 3D printer in the ‘Processing and Prototyping’ category this year’s R&D 100 Awards. This innovative system – the first commercially available 3D printer for fluidically-sealed devices – offers rapid, straightforward and reliable prototyping of microfluidic components, including chips, manifolds, connectors and other devices. Using cyclic olefin copolymer (COC) makes it easy and affordable to 3D print devices for almost any application. The prestigious R&D 100 Awards are the ‘Oscars of Invention’, providing a benchmark of excellence and identifying the top technology products of the past year. The winners are chosen by an independent panel of judges

Established in 2005, Dolomite Microfluidics has grown to be the world leader in the design and manufacture of high quality innovative microfluidic products. The company offers a broad range of modular microfluidic systems, modules and components – including pumps, chips, connectors, temperature controllers, sensors, accessories and custom-made components – as well as software for analysis or automation. Modularity, ease of use, innovation and scalability are common to all Dolomite products, which are used across a broad range of applications in biology, drug discovery, chemistry, food, cosmetics and academia. Dolomite is a part of the Blacktrace group of companies, a world leader in Productizing Science®, and has offices in the USA, Japan, India and Brazil, as well as a worldwide network of distributors.

Maneka Gandhi’s People for Animals Receives International Recognition for work in Animal Welfare India’s largest animal welfare organization headed by Union cabinet minister for Women & Child Development Smt. Maneka Sanjay Gandhi, People for Animals, has been awarded the prestigious UK based LUSH prize for its leadership and contribution to achieving historic legislations for animals in laboratories. For more than two decades, through its Chairperson, Smt. Maneka Sanjay Gandhi, People for Animals (PFA) has advocated for better legislation for animals in laboratories by promoting laws that move away from animal

experiments and adoption of non – animal alternatives. Smt. Gandhi has been recognized for her leadership in banning animal testing on household products such as soap and detergents, funding towards the country’s first centre for alternatives, her role in ending the archaic test on rabbit and skin test for drugs and for changing the syllabus for veterinary courses to include use alternative technology. On receiving the award which includes a cash prize of GBP 10, 000 Smt Gandhi said; “Laboratories are the second largest consumers of animals, second only to slaughterhouses. I am very pleased

that the tireless efforts of PFA, in bringing about a change in the way animals are used for experiments, have been recognized internationally. However, we have a lot more left to do and achieve and millions of animals to save. India and its scientific community must introspect and realize the limited role of animals. It is important that they progress to invest in and adopt far more advanced technologies which do not make the use of animals and are cheaper, more effective and humane.” Smt. Gandhi has also, in her tenure as a Member of Parliament in

the opposition lobbied for and achieved historic legislations such as prohibition of dissection in schools, dissection in zoology, pharmacy and undergraduate medical college in India. It was under her aegis as a Minister of Environment and Forests that the statutory body for regulation of animal experiments, Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) was formed. In addition to advocating for animal welfare policies in India, People for Animals have 200 units in the country along with 32 charitable animal hospitals.

Medical Device ASIA | January-February 2017 | 19


Celebrity fitness instructor Namrata Purohit Celebrity fitness instructor Namrata Purohit has been in news for introducing Pilates to the life of some of the fittest and most well known faces from fashion, Bollywood and society. She has instantly hit limelight and gathered a large following due to her innovative techniques making the workout so much more fun. Recently, she introduces yet another kind of workout to get you to come back to her studio. Namrata Purohit speaks about her new workout routine. “Pole fitness is one activity that targets not only the entire body, but also the mind and soul. I tried pole fitness for the first time while I was studying at Loughborough University and immediately fell in love with it. It didn’t take me more than 5 minutes into my first class to decide that this was something I want to bring to India, a fitness form that Indians need to experience. Throughout my class I found this new appreciation for pole dancers, and people who practice pole fitness. They make it look so beautiful, so effortless but it is hard, really hard. Your entire body needs to be in sync in order to be able to do a move, and look good while doing it. I felt each muscle in my body, my arms, core, legs everything was working, and I was also having a lot of fun. Like Pilates, I found pole to be something that worked the body and mind. It not only works on your strength but on flexibility, balance, stability, and most importantly builds your confidence. After finishing a pole fitness session, you feel strong, sexy, and beautiful and you tend 20 | January-February 2017 | Medical Device ASIA

to appreciate and love yourself even more. It is a very enlightening experience. There are many times in a pole class you will not know what you are doing, it does get complicated, but that is just part of the fun. You work your way through it and when you get it right it is the most satisfying feeling. Pole fitness is great for many reasons. It strengthens the core, burns calories, improves strength, flexibility, stamina, and balance, builds self-confidence, reduces stress, and is also something that will make you extremely happy. As I have always said fitness should be fun, and pole fitness is definitely a fun way to get fit. “


Jaypee Hospital wins ‘Emerging health brand of the year’ award • •

The awards were organised by the India Healthcare & Wellness Summit & Awards It was accepted by Jaypee Hospital CEO Dr. Manoj Luthra Speaking on the momentous occasion, Dr. Manoj Luthra, CEO, Jaypee Hospital said, “It’s a moment of pride for us. We are pleased to receive an award in the ‘Emerging health brand of the year’ category and promise to keep the spirit of serving the society alive. Recognitions like these always motivate one to work harder.” “The healthcare sector gives us an opportunity to serve the people in need and we are honoured that our hospital is being recognised for all the good work we have done for the society,” he added.

Jaypee Hospital, a multi super specialty hospital in Sector 128, Noida, won a prestigious award in the category ‘Emerging health brand of the year’. The awards were organised by the India Healthcare & Wellness Summit & Awards – 3rd annual edition at Hotel Taj Palace, New Delhi.

T

he award was received by Dr. Manoj Luthra, CEO, Jaypee Hospital by the leading film and T.V. actress Gautmi Tadimalla. Dr. Luthra also participated in a panel discussion on ‘Relooking at the basics of healthcare.’ It was a whole day event which included panel discussions and sessions addressed by industry veterans and leaders highlighting the trends prevalent in the healthcare sector.

The foundation of Jaypee Hospital was laid two years back in 2014 and in the past two years the hospital has treated more than 2 lakh patients. Recently, Jaypee Hospital has successfully completed more than 110 liver & renal transplants in a year. The hospital continuously strives towards achieving its vision of promoting world-class healthcare amongst the masses by providing quality and affordable medical care with commitment.

Brain dead man gives new lease of life to 3 people 50 year old Mahipal Singh, from Kamothe, had met with an accident on Tuesday, December 6th 2016 at Uran Highway, in Navi Mumbai. He was brought to Apollo Hospitals, Navi Mumbai, in a critical condition with severe head injury. In spite of the all the treatment, he did not recover and eventually was declared brain dead on Wednesday, December 7th, 2016, as per the protocols. The treating Doctors educated the family on organ donation and with the support of ZTCC [Zonal Transplant Coordination Center], the family agreed to donate his organs with all generosity. His liver and both the kidneys are being transplanted at private hospitals in Mumbai, giving a new lease of life to 3 people. Dr Narendra D. Trivedi, CEO, Apollo Hospitals, Navi Mumbai, said “Mahipal

Singh continues to be alive in these 3 individuals and we sincerely thank the generosity of the family. We also thank the media and ZTCC for their sustained support in educating the public on organ donation.” About Apollo Hospitals: Apollo Hospitals - Navi Mumbai, is a state-of-the art 500 bedded facility, with 120 Critical Care Beds and one of the most advanced Multi-

About Jaypee Hospital: The Noida based Jaypee hospital is the flagship hospital of the Jaypee Group, which herald the groups with a noble intention to enter the healthcare space. The hospital spreads across 18 acres of sprawling campus in the state of Uttar Pradesh. The hospital has been planned and designed as a 1200 bedded tertiary care multi-specialty facility and has commissioned 525 beds in the first phase. The Jaypee Group is committed to providing world-class healthcare supported by renowned consultants and most advanced technology. Jaypee Hospital is a super-specialty hospital with advance healthcare facilities, the latest diagnostic services, and state- of-the –art technology focused on medical specialties that meet the needs of masses. The plan, design and construction of this hospital position itself amongst very few GOLD LEED Certified hospitals building in India.

speciality Tertiary Care Hospitals in the region of Mumbai and Navi Mumbai. The hospital offers comprehensive and integrated super-speciality services under one roof with highly experienced doctors of national and international repute supported by a well-trained team of nurses & technicians and other support staff. The unit comprises of more than 50 specialties with accessibility to advanced technologies and clinical expertise.

Medical Device ASIA | January-February 2017 | 21


OGT expands Cytocell sarcoma FISH probe range Addition of three new sarcoma probes produces largest portfolio on the market Commenting on the latest launch of Aquarius FISH probes, Steve Chatters, Senior Product Manager for Pathology at OGT, explained: “These new probes clearly show OGT’s commitment to being a market leader for highquality FISH probes in the fast-moving field of cancer research; with over 20 new FISH probes released in the last year, Cytocell’s FISH portfolio is second-to-none in both range and quality. We are committed to keeping up with our customers’ expectations by further expanding the Cytocell cancer FISH probe range in 2017.” Thanks to their excellent specificity, Cytocell Aquarius FISH probes deliver high-intensity signals with minimal background fluorescence. Probes are supplied as ready-to-use, premixed solutions to minimise the risks of experimental errors, delivering confidence in results. Within the Cytocell portfolio, FUS Proximal Probe Red, FUS Distal Probe Green, FOXO1 Proximal Probe Green, FOXO1 Distal Probe Red, TFE3 Proximal Probe Red and TFE3 Distal Probe Green have been released as Analyte Specific Reagents (ASRs) in the United States. To find out more, please visit www.cytocell.com. For further information, please contact: Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K. [Cytocell Aquarius FOXO1 Breakapart on a formalin-fixed paraffin-embedded section with bright, robust signals]

T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech

Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its range of Cytocell Aquarius®

About Oxford Gene Technology

fluorescence in situ hybridisation (FISH) probes for

Oxford Gene Technology (OGT) provides worldclass genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™ and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.

pathology. OGT has introduced three new probes: FUS Breakapart and FOXO1 Breakapart, both carrying the CE-IVD label – and TFE3 Breakapart, for research use only. This expansion reinforces OGT’s commitment to providing the most comprehensive and up-to-date range available, facilitating cancer research and diagnosis.

D

eveloped in response to customer need, the genes for both FUS and FOXO1 are both implicated in several debilitating neoplastic diseases. Recurrent rearrangements involving the FUS gene with a

number of different partner genes have been reported in various types of neoplastic disease, notably soft tissue sarcomas and acute myeloid leukaemia. Translocations involving the FOXO1 gene are associated with around 80% of cases of alveolar rhabdomyosarcoma. 22 | January-February 2017 | Medical Device ASIA


MTA2017 to spotlight new technologies with specialised zones

In a global manufacturing outlook report, 49 per cent of manufacturers surveyed were reported to be investing six per cent of their revenues in R&D and innovation, in a push to transform their businesses. Asian manufacturing companies surveyed exhibited the highest investment expectations, with a majority of respondents from China, Japan and India indicating they would spend more than six per cent of their revenues on technology and innovation. 25 per cent of the respondents have already poured investment in avant garde technologies such as 3D printing. Riding on a wave of renaissance in the industry, MTA2017 – Asia’s premier manufacturing technology industry event returning from 4 to 7 April at the Singapore Expo, will kick off a host of new features - The Optics & Photonics Innovation Hub, The Semiconductor Innovation Centre, and a 3D Printing Seminar. “As manufacturing continues to evolve and value creation has become

an integral component of the change process, many traditional manufacturing businesses in the Asian region need to become agile and embrace change. The new features, along with the recurring Capabilities Hub, are designed to serve industry players who are looking to leverage on technology and innovation to maintain their market leadership and stay ahead of the change curve,” says Mr. William Lim, Project Director of Machinery Events at Singapore Exhibition Services, organiser of MTA2017. Lim adds, “More importantly, the newfound knowledge and skillsets will ensure that

companies and their workforce will be well-positioned for growth opportunities in the new manufacturing era.”

MTA2017: Spotlighting advanced technologies for high-value manufacturing Optics & Photonics Innovation Hub In collaboration with the Optics and Photonics Society of Singapore (OPSS), LUX Photonics Consortium and The Photonics Institute, the Optics and Photonics Innovation Hub is dedicated to showcasing products and services in the field of optics and photonics. This specialised zone will bring together industry and academic leaders,

Medical Device ASIA | January-February 2017 | 23


manufacturers and suppliers to showcase the latest research and innovative products. Soda Vision, Del Mar Photonics / Team Photon Inc, Wavelength Opto-Electronic, Sintec Optronics and PI (Physik Instrumente) Singapore are among some of the confirmed exhibitors in the zone. “MTA is a wonderful platform for both local and international industry players in optical engineering to share knowledge, network and support one another in the region. The Optics and Photonics Society of Singapore (OPSS) is pleased to participate in MTA2017 in the Optics and Photonics Innovation Hub, as well as organise the icOPEN2017 conference. Through these initiatives, we hope to continue building and reinforcing the connections between industry and academia,” says Professor Anand Asundi, Chairman of OPSS. “The LUX Photonics Consortium’s main objective is to bring industry and academia together to collaborate on photonics research and innovation, and provide access to our member companies to global photonics research and industry network. MTA is one of the most established events that gather companies in various vertical segments of the market which are enabled by photonics technologies. Our participation in setting up the Optics & Photonics Innovation Hub provides a platform for our member companies to showcase their products and services in the optics and photonics sector, and expand their industry and business networks effectively,” adds Professor Tjin Swee Chuan, Chairman of LUX Photonics Consortium. Some member companies of LUX Photonics Consortium confirmed to be participating at MTA include Finisar Singapore, Einst Technology, Hylax Technology, II-VI Singapore,

D’Optron, Tip Biosystems, Lighthaus Photonics and Hillhouse Technology. Semiconductor Innovation Centre According to the World Semiconductor Trade Statistics (WSTS), the worldwide semiconductor market is expected to increase 2 per cent in 2017 and 2.2 per cent in 2018. At MTA2017’s Semiconductor Innovation Centre, visitors can get up close and personal with advanced semiconductor manufacturing technologies and solutions made for the evolving global electronics market, and learn how harnessing these technologies and solutions will enable the industry to compete in the global market. Some companies on board include Sandvik South East Asia, ISO-Dynamique Microsystems and Onn Wah Tech. 3D Printing @ MTA Advances in additive manufacturing, or 3D printing as it is commonly known, have seen the application of more and more materials to the process and the creation of innovative solutions for the manufacturing industry. Besides a 3D Printing Technology Tour, a new 3D Printing Seminar will be held to impart technological updates, opportunities, issues and challenges impacting the industry. The National Additive Manufacturing Innovation Cluster and the Additive Manufacturing Innovation Centre by Nanyang Polytechnic will be featured on the show floor. Capabilities Hub A centrepiece at MTA, the Capabilities Hub gathers local parts and component manufacturers and service providers to highlight their manufacturing competencies in the high-value sectors of Aerospace, Complex Equipment, Medical Technology and Oil & Gas. Organised in partnership with the

24 | January-February 2017 | Medical Device ASIA

Singapore Institute of Manufacturing Technology (SIMTech), this area will see local and overseas players converge to network, exchange knowledge, discuss potential collaborations and forge partnerships. Confirmed exhibitors include CEI Limited, Microcast, Eratech, Solidmicron Technologies, Nano Technology Manufacturing, Onn Wah Precision Machining, Fujicon Engineering, Autec Solutions, ST Kinetics Integrated Engineering, JEP Precision Engineering and Wah Son Engineering, to name a few.

MetrologyAsia2017: Serving industry’s demands for precise engineering Metrology solutions are important to the manufacturing process, from miniature electronics, intricate medical devices and precision components to large aircraft structures and oil & gas parts. MetrologyAsia2017 is dedicated to showcasing cuttingedge metrology and inspection equipment and spotlighting companies specialising in high-end test and measurement apparatuses and systems. Attendees will learn

about the latest in metrology solutions from the top technology providers around the world.

Conferences for knowledge and skills upgrade In a rapidly changing business landscape, having the right information at the right time is essential to business sustainability and success. With knowledge sharing being a vital element, the conferences at MTA2017 are specially formulated to enhance industry professionals’ insights in new manufacturing concepts. The Smart Manufacturing Asia conference will have industry thought leaders and experts delving into pertinent topics and offering practical tips in digital manufacturing, Industry 4.0, robotics and industrial automation. The Precision Engineering Centre of Innovation (PE COI) Annual Conference and the International Conference on Optical and Photonic Engineering (icOPEN), both having seen highly successful editions, will return to debate on latest trends and issues facing the precision engineering industry.

MTA2017 - Manufacturing Technology Asia (held alongside MetrologyAsia2017) at A Glance: Incorporating: iAutomation2017, MetalAsia2017, Outsource&SubCon2017, ToolTec2017 Date: 4 – 7 April 2017 (Tuesday - Friday) Venue: Singapore Expo Opening Hours: 10.30am to 6pm daily Admission: Business and trade professionals Website: www.mta-asia.com Visitor registration: www.mta-asia.com/to-visit/visitor-pre-registration/

About Singapore Exhibition Services Pte Ltd Singapore Exhibition Services organises a portfolio of international tradeshows serving the Communications, Engineering, Machinery and Lifestyle industries. Our events consistently attract a high level of overseas participation with foreign exhibitors accounting for almost 80% of the show floor. Singapore Exhibition Services is a member of Allworld Exhibitions Alliance, a global network with over 50 offices worldwide. Please visit www.sesallworld.com for more information.


Semperit Group with stable operational development in H1 2016 • Revenue with EUR 438.7 million (-2.7%) slightly below previous year’s level despite market weakness • Improved EBITDA (+4.8%) and stable EBIT (+/-0.0%) • Persistently challenging market environment expected for the second half of 2016

The publicly listed Semperit Group generated a stable operational development in the ongoing difficult market environment of the first half of 2016. Despite the weak economy, Semperit generated a further increase in revenue with high profitability in the Industrial Sector. This allowed for largely offsetting the weaker development of the Medical Sector. Group revenue amounted to EUR 438.7 million in the first half of 2016 and was slightly below the previous year’s figure of EUR 450.8 million. Semperit improved the group’s EBITDA by 4.8% to EUR 52.8 million (after EUR 50.3 million). EBIT was stable in comparison with the previous year at EUR 36.2 million (after EUR 36.2 million). The EBITDA margin and the EBIT margin improved slightly to 12.0% (after 11.2%) and 8.3% (after 8.0%) respectively. “Due to our strong sales performance, a capacity utilisation above the industry average and new capacities in the Industrial Sector, we showed a stable operational development in the first half of 2016. However, the low demand in economically sensitive fields and the cost pressure due to rising energy and raw material prices combined with weak sales prices in the glove business are beyond our influence. We are taking countermeasures by using a focused sales strategy and programmes for optimisation and efficiency enhancement as well as by opening up new markets. This and our new highly efficient production sites make us well prepared to perform better than the market even in the current environment,” CEO Thomas Fahnemann comments on the half-year results. In the second quarter of 2016, the Industrial Sector achieved further revenue growth as opposed to a decrease in revenue and earnings in the Medical Sector. Corporate revenue decreased to EUR 219.2 million (after EUR 233.4 million) in the second quarter of 2016. EBITDA declined to EUR

26.1 million (after EUR 28.5 million) and EBIT to EUR 17.6 million (after EUR 21.0 million).

million in the first half of 2016. EBITDA climbed 2.3% to EUR 52.3 million.

Semperit boasted a sound capital basis as reflected by its equity ratio of 36.7% at the reporting date of June 30, 2016 (December 31, 2015: 38.7%). Cash and cash equivalents amounted to EUR 133.0 million on June 30, 2016 compared to EUR 126.4 million at the end of 2015. “Our cash balance has increased again, although we currently run the largest investment programme in corporate history and we have paid an attractive dividend in the second quarter. This positive development shows our high ability to generate cash even in a difficult environment,” states Semperit CFO Johannes Schmidt-Schultes.

Medical Sector: Difficult market environment

Industrial Sector: Increase in revenue and earnings The Industrial Sector (Semperflex, Sempertrans and Semperform segments) showed a very satisfying development contrary to the market trend. The Semperflex segment generated continuing high profitability thanks to excellent production and sales performances in a declining market. The Sempertrans segment was able to defend its positioning in core markets and expand its market position in new regions and market segments. In a weak market environment, the Semperform segment profited from the successful integration of the German profile manufacturer Leeser, as well as the increase in market share in the handrail business. Revenue of the Industrial Sector rose 3.7% to EUR 269.0

The Medical Sector (Sempermed segment) was impacted by a difficult market environment. During the reporting period, increased energy and raw material prices could not be passed on to the market yet due to high competitive and price pressures. The burdening influences of the cooperation with the joint venture partner in Thailand continued and increasingly have a negative effect on the earnings situation of the segment. Additionally, non-recurring costs related to the ongoing capacity expansion in Malaysia were experienced and more lowmargin trade items were sold. Revenue of the Medical Sector decreased by 11.4% to EUR 169.7 million in the first half of 2016 due to heavy price pressure and the focus on high-margin customer relationships. EBITDA decreased to EUR 7.9 million (after EUR 11.6 million). Compared to the first half of 2015, when Semperit still entered exceptionally high foreign currency gains, the foreign currency effects were overall negative in the first half of 2016. Moreover, interest expenses and income taxes due to non-recurring effects had increased. In summary, the Semperit Group generated earnings after taxes amounting to EUR 17.9 million (after EUR 25.3 million) in the first half of 2016 despite the stable operational

Medical Device ASIA | January-February 2017 | 25


results.

Outlook 2016 Semperit expects no significant changes of the market conditions for the second half of 2016. The generally low demand in the Industrial Sector is expected to continue due to the current economic situation. Demand in the economically insensitive Medical Sector is expected to develop steadily with higher raw material and energy costs and continuing price pressure. From the current perspective, the Semperit Group is not capable of achieving the operational results of 2015 due to the unsatisfactory income contribution of the Sempermed segment. In the Industrial Sector, Semperit refers to a good order situation for the next months, even though a slowdown is possible in some business segments. In the Medical Sector, the focus will be on the implementation of further production capacities in Malaysia. The profitability shall be improved by continuing process optimisations and efficiency enhancements as well as realising a cost reduction programme. The burdens due to the Thai joint venture will probably persist.

About Semperit The publicly listed company Semperit AG Holding is an internationally-oriented group that develops, produces, and sells in more than 100 countries highly

The Semperit Group will continue its growth strategy consistently despite challenging conditions. The focus will be on entering into new markets in the Industrial Sector and on the expansion and optimisation of existing production capacities. In the Medical Sector, the focus will be set on the expansion of the glove production in Malaysia in addition to further production and sales optimisations as well as efficiency enhancements. Altogether, capital investments (CAPEX) of approximately EUR 60 million are planned for 2016.

specialised rubber products for the medical and industrial sectors: examination

As of now, the report on the first half of 2016 is available at www. semperitgroup.com/ir.

sales offices in Europe, Asia, Australia and America. In 2015 the group

26 | January-February 2017 | Medical Device ASIA

and surgical gloves, hydraulic and industrial hoses, conveyor belts, escalator handrails, construction profiles, cable car rings, and products for railway superstructures. The headquarters of this long-standing Austrian company, which was founded in 1824, are located in Vienna. The Semperit Group employs more than 7,000 people worldwide, including about 4,000 in Asia and more than 800 in Austria (Vienna and production site in Wimpassing, Lower Austria). The Group has 22 manufacturing facilities worldwide and numerous generated sales of EUR 915 million and an EBITDA of EUR 96 million.


Semperit AG Holding:

Sempermed Builds New Glove Factory in Malaysia

– largest investment ever made by Semperit

The Semperit Group is expanding production capacity at the Kamunting, Malaysia site of its Sempermed segment. A total of about EUR 50 million (MYR 220 million) will be invested in the period 2014 – 2016 to build a new glove factory. This is the largest investment in capacity increase ever made in the history of Semperit. Construction of the new facility will take place on the premises of the Kamunting plant, where Semperit has been operating six production facilities for medical and protective gloves since its acquisition of Latexx Partners Berhad in 2012. The first gloves are expected to leave the production lines starting in the middle of 2015, with the entire project scheduled for completion at the end of 2016.

Next step in the growth strategy “The integration of Latexx Partners into the Sempermed segment was successfully concluded last year. The capacity expansion drive at Latexx Partners will enable us to strengthen our position on the global glove market and move a decisive step closer towards achieving our designated growth targets”, says Thomas Fahnemann, Chief Executive Officer of Semperit AG Holding. “We can only reach this goal by offering competitive production costs. For this reason, the new facility will deploy state-of-theart technologies as the basis for a high level of automation and the optimal use of natural resources. It will be one of the world’s most efficient manufacturing plants for nitrile gloves”, CEO Fahnemann continues. Production speed will be significantly increased compared to the performance of existing factories. The new facility will also boast 50%

lower gas consumption, and electricity needs will be about 20% less than for conventional glove manufacturing technologies. The new investments will lay the groundwork for Sempermed to continue its expansion path on the growth market for examination gloves featuring an increase in demand of about 5-7% annually. About Semperit The publicly listed company Semperit AG Holding is an internationally-oriented group that develops, produces, and sells in more than 100 countries highly specialised rubber and plastic products for the medical and industrial sectors: examination and surgical gloves, hydraulic and industrial hoses, conveyor belts, escalator handrails, construction profiles, cable car rings, and products for railway superstructures. The headquarters of this long-standing Austrian company, which was founded in 1824, are located in Vienna, and the global R & D centre is in Wimpassing, Lower Austria. The Semperit Group employs about 10,800 people worldwide, including more than 8,000 in Asia and more than 700 in Austria (Vienna and production site in Wimpassing, Lower Austria). The Group has 22 manufacturing facilities worldwide and numerous sales offices in Europe, Asia, and America. In 2013 the Group generated sales of EUR 906 million and an EBITDA of EUR 133 million. About Sempermed Sempermed is the largest segment in the Semperit Group, and ranks among the world’s leading manufacturers of medical and industrial gloves. The research centre of Sempermed located in Wimpassing, Lower Austria continuously develops and tests new products in cooperation with users and experts. Sempermed has been producing gloves of the highest quality for more than 90 years, and as the world’s technology leader sets standards in quality and innovation. Sempermed guarantees optimal safety and reliability thanks to state-of-the-art manufacturing technologies, the highest attainable production hygiene and the strictest quality controls. In 2013, the Segment Sempermed generated revenue of EUR 435 million (approx. 48% of Group revenue) and an EBITDA of EUR 59 million. Medical Device ASIA | January-February 2017 | 27


Draft Medical Device Rules fall short of the expectations of the medical devices sector – AdvaMed Medical device rules 2016 need better harmonization with global regulatory practices and ensure operational ease of doing business

The Advanced Medical Technology Association (AdvaMed) – a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world – has submitted its comments on the medical device draft rules 2016. The rules in its current form lack harmonization with international norms of medical device regulation, which is necessary to provide the necessary fillip to the sector that provides extraordinary growth opportunity for the country through creation of high paying jobs, economic value and better patient outcomes. In addition to the device rules, the Association also, strongly, recommends inclusion of the globally harmonized definition of medical devices into the current Act, which is not part of the drug definition. Varun Khanna, Chairman, Advamed India Working Group, and Executive Committee Managing Director, BD India & South Asia said, “All policy decisions need to be based on scientific due diligence. The Medical device draft rules 2016, at this stage, need more clarity and alignment with global best practices to fully meet the sector specific requirements in order to ensure predictability in the Indian market, which is a critical factor when it comes to investment decisions. The current rules address some but not all of the issues that were deliberated upon during several industry

consultations while working on this draft. AdvaMed and its members appreciate the efforts made by the Indian Government to improve the overall landscape for medical devices. We request the Government to continue consultations with the innovative industry and build on their experience to come up with a methodology that will address reasonable concerns around access and affordability while promoting research and med-tech innovation.” He also said, “The government needs to be mindful of the fact that without sufficient capacity it will be challenging for them to implement these rules. Therefore, a critical step for the successful implementation of the medical device rules would be to take measures for building capacity of the relevant ministries and ensure greater understanding of the sector dynamics and criticalities among the regulators.” The association members have urged the regulators to make necessary revision in provisions that hinder operational ease of doing business for the device companies. For instance, the additional requirement for clinical investigation of medical devices already approved in GHTF countries shall cause unnecessary delay in the availability and access of innovative Medical Device ASIA | January-February 2017 | 29


medical devices to the HCPs and the patient population. Moreover, the provisions with respect to labeling of medical devices should be aligned with the Draft rules published in July 2016, and the clause with respect to the shelf life of medical devices should be amended to be in line with global requirements. The members said that while the implementation of UDI is a positive step, it is imperative for the government to have realistic timelines. For example, as per the US and EU implementation timeline, the complete implementation including direct part labeling will be over only by 2022. Hence, it is premature to incorporate this in the current rules, as manufacturers are not ready for implementation of UDI. AdvaMed and its members are committed to work closely with the concerned departments and ministries to extend all the cooperation in nurturing a conducive environment for increased investment and sector growth. The association said that encouraging measures for medical device regulation would enhance penetration of essential medical devices, and it is hopeful that its perspective would be reflected in the final version. Annexure Listed below are some of the critical issues submitted by AdvaMed: 1. There should be inclusion of definition of Medical Devices in D&C Act prior to final publication of these rules. 
 2. There should be voluntary registration for first 2 years and then mandatory. For a company that has thousands of products already marketed in India, 180 days is too short to apply for a license for all of them. 
]

3. Clarification to be published w.r.t a. exclusion of R&D Activities from definition of Manufacture. 
 b. Exclusion of Seller and Distributor from the definition of Manufacturer
 4. Rule 32 a. (2)A licence shall be granted under sub-rule (1) if the medical device is having free sale 
certificate /CFG/ Approval/ equivalent certificate from the national regulatory authority or competent authority of the United States of America, European Union countries, Canada, Australia or Japan. 
 b. (3) Where the medical device is approved in countries other than those referred to in sub-rule (2), the licence in case of Class C and Class D medical devices may be granted after its safety and effectiveness has been proved or established through clinical investigation / equivalence in India as specified under Part VII of these rules. 
 5. Clinical: a. Following to be defined as per IMDRF : I. clinical evidence 
 II. clinical evaluation 
 III. Unexpected serious adverse event: It is an adverse event considered “unexpected” if it is not listed in the investigator brochure and/or is not consistent with the risk information described in the general investigational plan or elsewhere in the current application. 
 IV. Serious adverse device effects: It is an adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event. 
 V. Device deficiency: It is an inadequacy of a medical device related to its identity quality durability reliability, safety or performance, such as malfunction, misuse or use error and inadequate labeling 
 b. Remove annual income as it is not relevant to

30 | January-February 2017 | Medical Device ASIA

the clinical investigation and may create bias 
 c. In general there are discrepancies between Good Clinical Practice Guidelines and this Rule including the Seventh Schedule. All Clinical trials are required to be compliant to both the Rule and GCP. Examples include different definitions e.g. Serious Adverse Event and Sponsor; the term Protocol versus Clinical Investigation 
Plan Different formats, and requirements for CIP versus Protocol. 
 d. Medical Management & Compensation Rules: The compensation / medical 
management to be recommended only if injury to patient is attributed to the failure of Medical Device. 
 e. Safety and effectiveness should be established through clinical investigations / equivalence / published data or leveraging the clinical data on similar / equivalent products. 6. The requirement of Plant registration document for obtaining import licence should be deleted as most countries do not have the concept of Plant registration. 
 7. Change in Constitution is not recognized in company’s act and neither exists in global regulatory practices. For major international corporations with many subsidiaries, this could be burdensome, drive and drive unnecessary filings. Major changes would be captured by proposed alternate language. The change Management Regulations to be governed in alignment with GHTF / IMDRF change decision tree and recommendations shared earlier by the Associations. 
 8. Fourth Schedule, Part III, Appendix II, a. Item 7.8 Shelf Life data – Real time or accelerated either of the two studies should be 
acceptable whichever is available. Both studies submission shouldn’t be mandatory. 


b. “Batch release certificate of 3 consecutive batches” to be replaced with “Batch release 
certificate or Certificate of conformity of any three batches” 
 9. Labeling: a. To be aligned with existing Rule 109A which states labeling on shelf pack and every outer covering. “...on every outer covering in which the medical device is packed” is unfeasible, as it makes no distinction between sales packaging and distribution packaging. As written, this would apply to a 15 ft, 6000 lb air freight container. 
 b. Labeling to be exempted on any wrapper, covering used for shipment, transportation or delivery purposes. This is existing provision in Rule 96 of Drugs & Cosmetics Rules. 
 c. “Provided further that when the device is made up of materials such as stainless steel or titanium and supplied non-sterile, date of expiry may not be necessary;” Why would this be limited to stainless steel or titanium? There are many types of non-sterile device, made from many materials. Expiration is a function of tested sterile barrier performance, and would not apply to non-sterile products. 
 d. Stickering / stamping for Physician’s Sample Not to be sold and Hospital Supply only should be allowed at commercial warehouse as unlike Pharmaceuticals the forecast of unit to be implanted in patient is not known earlier. The product post stickering and stamping to be released post QA check and proper records to be maintained for the same. 
 e. UDI to be removed from existing draft and should be included post FY2020. 
 f. Shelf life capping should be 8-10 years for Medical Devices instead of 5 years - 
Global Practice. 



Union Budget 2017-18

AIIMS TO BECOME CASHLESS WITH MOBIKWIK In the wake of demonetization, AIIMS (All India Institute of Medical Sciences) Delhi, India’s premier medical institution has partnered with MobiKwik to convert all its payment facilities cashless. To commence with; resident doctors, staff and visitors can pay with MobiKwik in the institution’s cafeteria. Payment of doctor’s consultation, tests and other services will be made cashless by the first week of January 2017. AIIMS is a medical college and medical research public university based in New Delhi, India. The Institute was established in 1956 and operates autonomoustly under the Ministry of Health and Family Welfare. Daily, over 25000 patients visit the facility to receive best in class treatment for their ailments. Upasana Taku, cofounder of MobiKwik added on the association, “We are proud to support Indians during the current situation of cash crunch and lead India’s transformation into a less-cash economy. AIIMS is the foremost medical institution in India and we are glad to have partnered with them.” MobiKwik is an Indian mobile wallet major with 45 million users. The company has also launched an under 1 mb app, MobiKwik lite to support masses with low data connectivity and dated smartphones with technology limitations in accessing mobile payments.

About MobiKwik: MobiKwik is an Indian wallet major with a network of more than 10 lakh direct merchants and over 45 million plus users. Founded in 2009 by Bipin Preet Singh and Upasana Taku, the company has raised three rounds of funding from Sequoia Capital, American Express, Tree Line Asia, MediaTek, GMO Payment Gateway, Cisco Investments and Net1. MobiKwik aspires to be the largest source of digital transactions in India. It is powering e-payments for IRCTC, Uber, Meru Cabs, Big Bazaar, OYO Rooms, Zomato, PVR, Archies, WHSmith India, BookMyShow, Grofers, Big Basket, Dominos, Burger King, Pizza Hut, eBay, ShopClues, Myntra, Jabong, Pepperfry, Barista, Food Panda, Nearbuy, Van Heusen, Allen Solly, Louis Phillips, GoDaddy, MakeMyTrip.

Incentivise investment for MedTech manufacturing to accelerate ‘Make in India’; custom duty hike needs a roll-back The import duties on medical devices and equipments have already been increased almost across the board by 7.3% in January 2016. Since most of the items affected were falling in the 11.6% range which has gone to 18.9% now, it means an effective duty increase of 62.7%. “For products where the ability to import substitute is still far away, the high custom duties should be rolled back. Such custom duty increases, which are almost fully passed on to patients, will only tax the patients further due to increase in cost of treatment,” Pavan Choudary, Director General, Medical Technology Association of India (MTaI) said. “Moreover, since the custom duty regime in the neighbouring countries (Nepal, Bangladesh, Sri Lanka, Bhutan, Pakistan, Maldives & China) is now much lower than in India, the differential in duties created is likely to lead to the smuggling of many of the low-bulk-high-value devices. As that happens, not only will the Government lose revenue but also the patient will be beset with products without adequate legal & service guarantees,” he added. There is an urgent need to do the micro analysis of the sub sectors to know the requirements. Wherever import substitution of an acceptable quality level is not on the anvil, a duty roll back to previous levels should be made. Where such substitution can happen, the duties can be kept at the levels where they are, since they have had a disproportionately high climb last year, and these can be then gradually increased after a couple of years provided the duty level does not go way beyond what is there in neighboring countries and if quality deficient manufacture doesn’t find their way in to the market. In the absence of any immediate remedy, we will clearly find mortality traps gaping at us. A process of incentivization (including lowest possible tariffs on raw material & components), research & development, skill development, greater health expenditure or better insurance coverage, low regulatory costs, assurance of predictable policy, will benefit the cause of Make in India rather than custom duty increase. About MTaI: Medical Technology Association of India (MTaI – pronounced as Emtai) is a not-for- profit organisation duly registered under sub-section (2) of section 7 of the Companies Act, 2013 and Rule 8 of the Companies (Incorporation) Rules, 2014. MTaI is an association of research-based medical technology companies who have made remarkable investments by setting up large number of R&D centres and manufacturing plants in India. MTaI represents a wide spectrum of the medical device and equipment industry with global experience in innovation and manufacturing. All the time stressing on the three hallmarks of healthcare - Quality, Consistency and Patient Safety, MTaI want to be a responsible voice of the industry. The association is committed to improving access to affordable and quality healthcare for patients. MTaI looks to partner with Government of India in setting a roadmap for growth of medical devices sector by bringing in even bigger investments in this sector, through ‘Make in India and through technology upgradation and dissemination in the provider space. Medical Device ASIA | January-February 2017 | 31


BioPharmX Data Suggest Anti-Inflammatory Activity of BPX-01 Topical Minocycline Gel Poster presentation at ODAC Conference reports potential anti-inflammatory properties of minocycline in unleashing both an antibacterial and anti-inflammatory properties simultaneously is critical to clearing acne lesions more effectively.” BPX-01 is the first and only stable hydrophilic (non-oil-based) topical gel with fully solubilized minocycline that can penetrate the skin to deliver the antibiotic to where the acne develops in the pilosebaceous unit. The company’s studies are designed to confirm whether BPX-01 can effectively treat acne with lower, and potentially safer, dosages of the antibiotic. BioPharmX recently announced the on-time completion of enrollment in the OPAL (tOPicAL Minocycline Gel) study – a Phase 2b dose finding clinical trial to assess the efficacy and safety of BPX-01 for the treatment of acne vulgaris. The 12-week, multi-center, randomized, double-blind, three-arm, vehiclecontrolled OPAL study involves 225 individuals, aged 9 to 40, who have moderate-to-severe inflammatory, non-nodular acne vulgaris. The American Academy of Dermatology calls acne the “most common skin condition in the United States,” affecting 40 million to 50 million Americans. The U.S. market for acne medications is estimated at $10 billion. BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will share research findings at this week’s Orlando Dermatology Aesthetic & Clinical (ODAC) Conference, which suggest that topical minocycline may reduce P. acnes-induced inflammation. The data will be shared in a poster presentation titled “Involvement of Sebaceous Gland in Acne Pathogenesis,” at ODAC. The study, part of BioPharmX’s development program for its unique BPX-01 topical minocycline formulation, suggests that minocycline’s antiinflammatory properties may be delivered in a topical formulation to target P. acnes-stimulated sebocytes. To effectively treat P. acnes with minocycline, the product must also take advantage of minocycline’s anti-inflammatory properties. Recent studies have found that inflammation – long thought to be a side effect of P. acnes – may actually be one of the condition’s underlying causes. “Our research suggests that the anti-inflammatory benefit of minocycline can be delivered preferentially to a target area using BPX-01, our topical minocycline gel,” said Kin F. Chan, executive vice president of research and technology at BioPharmX. “The potential of a topical targeted approach 32 | January-February 2017 | Medical Device ASIA

About BioPharmX® Corporation BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in dermatology and women’s health. To learn more about BioPharmX, visit www.BioPharmX.com. Forward-Looking Statement The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. This press release contains forward-looking statements about the company’s expectations, plans, intentions and strategies, including, but not limited to, statements regarding, the safety and medical effects of BPX-01, the effect BPX-01 may have on the treatment of acne, whether minocycline’s anti-inflammatory properties may be delivered in a topical formulation to target P. acnes-stimulated sebocytes, commencement and results of future tests involving BPX-01, continued and consistent results in future tests of BPMX-01 and absence of side effects of future use of BPX-01. These forward-looking statements may be identified by words such as “plan”, “expect,” “anticipate,” “believe,” or similar expressions that are intended to identify such forwardlooking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company’s filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. BioPharmX is a registered trademark of BioPharmX, Inc.


Cervical cancer is preventable

Cancer screening, and HPV vaccination - key to prevention Authored by Dr Lata Kini, Lead Clinical Pathologist

Ask any 10 women in India whether they have ever undergone cervical cancer screening and about 9 of them would have not. Despite the readily available and convenient screening modalities in the form of Pap smear test or liquid based cytology that can help prevent cervical cancer or detect it in its asymptomatic stage, most women in India do not undergo regular cervical screening. As a result, an overwhelming number are diagnosed with the disease in an advanced or invasive stage, by when it becomes difficult to treat. While cervical cancer is one of the deadliest cancers in women worldwide, it is also one of the easiest to prevent. However, lack of awareness about the disease, its causes, preventive measures as well as the need for screening makes it the leading cause of mortality due to cancer in women across the world. According to World Health Organization, more than 270,000 deaths are attributed to cervical cancer, with 85% occurring in developing countries like India. An estimated 132,000 new cases are diagnosed annually in India and 74,000 deaths are reported. India, therefore accounts for almost one third of the global cervical cancer deaths. On a brighter note, most of these deaths can be prevented if cervical cancer screening becomes a norm in India, along with vaccination for sexually transmitted HPV virus that is the leading cause of cervical cancer.

Early cervical cancer has no symptoms

Cervical cancer is the second most common cancer in women aged 1544 years, affecting the cervix- the lower part of the uterus that connects it with the vagina. Most cases of cervical cancer are caused by sexually acquired infection of some strains of the Human Papilloma Virus (HPV). With the advent of an authentic, non-invasive and cost effective screening technique, the incidence of this cancer has decreased manifolds, especially in the western world where most countries have instituted large scale screening programs for this disease. However, in India thousands of women continue to die every year from cervical cancer, particularly in rural areas where it still causes greater mortality than breast cancer. If you are experiencing any abnormal vaginal discharge or bleeding, discomfort during sexual intercourse or general pelvic pain, make sure you consult your doctor immediately as these symptoms may be warning signs of cervical cancer. Other symptoms of the disease include loss of appetite, weight loss, fatigue, back pain, leg pain, swollen legs, bone fractures, and/or (rarely) leakage of urine or feces from the vagina. Bleeding after douching or after a pelvic examination is another common sign of cervical cancer. Yet, in most cases cervical cancer does not present with any signs until it has spread well past the cervix to other parts of the body. The disease can be detected in pre-cancerous stage only through regular screening.

Cervical screening: The tests and guidelines

Cervical screening is the best way to detect cervical cancer at an early stage, and increases the rate of successful treatment. Cervical cancer screening requires a doctor or a nurse who takes the exfoliated cells from the surface of the cervix and a pathologist who detects early changes of cancer, if present. Liquid based cytology (LBC) and PAP tests are the two main methods of cervical screening. Both these tests are non-invasive and essentially painless. These tests are important for disease prevention, as they help in detecting any abnormal cell growth in the cervix before it turns cancerous. Screening is recommended for women between 21 and 65 years as majority of women diagnosed with cervical cancer are under 50 years of age; very few are over 65 years of age. The guidelines:

• Cervical screening (PAP or LBC) should start at the age of 21 years and should be performed after every three years till the age of 65 years. • It is discouraged before this age regardless of sexual initiation or other high risk factors. • Women can also get a combined Human Papilloma virus (HPV) test and PAP test every 5 years starting at the age of 30 years. • If any abnormality is detected, the testing should continue for 20 years from the time of detection.

HPV Vaccination

About 6.6% of women are estimated to harbor cervical HPV infection at any given time. Almost 75% of all sexually active adults are likely to be infected with at least one HPV type in their lifetime. While a majority of the HPV infections resolve on their own, some of them turn cancerous. It takes 15 to 20 years for cervical cancer to develop in women with normal immune systems. It can take only 5 to 10 years in women with weakened immune systems, such as those with an untreated HIV infection. There are currently 2 vaccines that protect against both HPV 16 and 18, known to cause at least 70% of cervical cancers. Clinical trials have found these vaccines to be safe and effective in preventing infection with HPV 16 and 18. The vaccines must be administered before the first sexual activity. WHO recommends vaccination for

girls aged 9-13 years as this is the most cost-effective public health measure against cervical cancer. If every female adheres to current HPV vaccination programs, cervical cancer rates will be reduced substantially. However, HPV vaccination does not undo the need for cervical cancer screening, which is recommended for all women, even those who have undergone vaccination.

Other risk factors include: • Long-term use of hormonal contraceptives • Early initiation of sexual activity • Multiple sex partners • Tobacco smoking • Co-infection with HIV • Poor hygiene • Diet low in antioxidants Treatment trends Treatment options vary according to the stage of the cancer and other clinical factors that include maintaining fertility and pregnancy. • Early cervical cancer is treated by various surgical modalities that include cryosurgery, laser surgery, cold knife conization, loop electrosurgical excision procedure, and hysterectomy. • If the cancer spreads to the lymph nodes and lymph vessels, a radical hysterectomy with the removal of pelvic lymph nodes is done. • Advanced cancers require surgery, radiation and chemotherapy. Various targeted drugs are also added to the chemotherapy regimen.

Medical Device ASIA | January-February 2017 | 33


‘Transasia on the Move’ wins hearts in the Pink City

‘Transasia on the Move’, the mobile van from Transasia BioMedicals Ltd. has been traversing through different parts of North India in its mission to bring quality diagnostic solutions to the doorstep of Doctors and Lab owners.

J

aipur, most famously known as the Pink City, recently played host to the 65th Annual Conference of IAPM and Annual Conference OF IAP-ID (APCON 2016) held between 1st- 4th December, 2016. This time too Transasia Bio-Medicals Ltd. was the principal partner of this conference. The star attraction was the presence of ‘Transasia on the Move’, flagged off by Dr. Kusum Mathur (Prof. & Head of Dept.-Pathology, SMS Medical College, Jaipur) at the venue. It received an overwhelming response from the over 1000 national and international pathologists & clinicians, who had converged at APCON 2016. Besides Jaipur, the van has been covering not just cities but even small towns of Rajasthan including Bharatpur, Alwar, Sikar, Jhunjhunu, Churu, Nagaur, Bikaner, Hanumangarh and Ganganagar. This special promotional vehicle, a first-of-its kind in the Indian In-vitro Diagnostic Industry, offers an interactive platform for showcasing the comprehensive range of product portfolio and reaching out to meet the needs of Doctors and lab technicians across the country, giving them an opportunity to familiarize with the latest technologies in diagnostics.

About Transasia Bio-Medicals Ltd. Incepted in the year 1979, Transasia Bio-Medicals Ltd., is headquartered in Mumbai, India. It is recognized as India’s Largest In-vitro Diagnostic Company and offers solutions and products in Biochemistry, Hematology, Coagulation, ESR, Immunology, Urinalysis, Critical Care, Diabetes Management, Microbiology and Molecular Diagnostics. Infact, Transasia is the first Indian company to manufacture and export sophisticated, stateof-the-art blood analyzers and reagents. Transasia is a part of the global Erba Diagnostics Mannheim GmbH Group. 34 | January-February 2017 | Medical Device ASIA

The Erba -Transasia Group has spread its footprint across USA, UK, Europe, Turkey and Eastern Europe, Russia and France, by means of various acquisitions – Erba Germany, Erba Czech Republic, Erba Russia, Erba Turkey, Erba France, Erba Diagnostics (USA), Erba Molecular (UK), Diamedix (USA), Delta Biologicals (Italy), ImmunoVision (USA), JAS Diagnostics Inc. (USA) and Drew Scientific (USA). Today, the Erba -Transasia Group serves millions across 100 countries. Recently, the Erba -Transasia Group has added another feather to its cap by acquiring Lumora, a UK based patented molecular technology company. This makes the Group, one of the selected few global companies with its own patented technology for molecular testing. Transasia manufactures and markets equipment and reagents, with an impressive install base of above 50,000 equipments across India. The vast network of more than 180 service engineers, 350+ Sales and Marketing Team, 16 zonal offices, and 350+ Distributors allows us to reach out to customers across the length and breadth of the country. Its foray into indigenous research has resulted in development of state of the art products and technologies, enabling Transasia’s deliverables to be synonymous with the best in the world. Alliances with international partners like Sysmex Corporation (Japan), Medica (USA) and Diesse (Italy) have ensured that cutting edge technology and solutions is brought to India. Transasia markets, services and supports the Sysmex products and solutions in India. All along its journey spanning more than three decades, Transasia has been recognized for its commitment to healthcare. The Economic Times, recently adjudged Transasia as the ‘Best Healthcare Brand-2016’. Besides this, Transasia has also been conferred ‘Pioneer for the Make in India Concept’ Award, by the Hon’ble Minister of Science & Technology & Earth Sciences, Government of India and ‘Global Growth Company-2014’ by the World Economic Forum amongst many others. With a vision of being recognized as a ‘local for global’ organization, Transasia continues to provide doctors and patients with reliable, affordable and innovative Medical Diagnostic Systems.


MediWorld - China International Medical Travel Show launches in 2017 as China’s premier health tourism event Uniquely addresses the world’s greatest current surge in medical tourism; announces dates, venue

China’s premier outbound medical tourism event, MediWorld - China International Medical Travel Show, today announced it will take place at the Portman Ritz-Carlton in Shanghai’s exclusive Jing’an district, Friday 12th May to Sunday 14th May 2017. This timely exhibition and conference is expected to attract more than 5,000 affluent Chinese visitors with an interest in overseas travel for medical, wellness, fertility, anti-aging and beauty treatments, as well as 2,000 healthcare practitioners, hospital managers and medical tourism industry professionals from China and many other countries. More than 50 of the world’s leading international hospitals and clinics, second opinion providers, medical tourism facilitators, and online health and telemedicine platforms from the US, the UK, Europe and Asia-Pacific are expected to exhibit at MediWorld to meet prospective customers, start a dialogue with Chinese partners and gain their share of the huge Chinese healthcare market. The MediWorld theme, “Where China meets the world of medical tourism” captures the intent and essence of the event. China is a rapidly growing outbound medical tourism market already worth over USD10 billion[1] and motivated by quality of care and travel experiences – not cost. A wave of medical travellers from China, with over 500,000 trips made in 2016[1], is being driven by major changes in demographics, epidemiology and an increasing ability to spend on medical care. (Source: [1] Global Growth Markets)

The MediWorld conference is an important aspect of the event, with a carefully thought-out program featuring world-class speakers from leading Chinese and international healthcare providers and other important stakeholders such as insurers, technology providers, investors and law firms. The two days of learning and networking will bring delegates up to speed on the latest strategies and opportunities in the industry – from both the business and clinical perspectives. “High acuity Chinese patients seek treatment overseas to access new or experimental drugs and innovative technologies. I’m seeing a significant rise of the Chinese patient in healthcare destinations everywhere—from expensive elective procedures, to health check-ups and wellness treatments combined with an international business trip or a memorable travel experience,” said Josef Woodman, CEO of Patients Beyond Borders and member of the MediWorld Board of Advisors. Many high net worth Chinese patients look to locations such as

the US, the UK, Germany, Turkey, Israel, Japan and Singapore for high quality health services and their reputation for medical excellence. Meanwhile, hundreds of thousands of affluent patients are heading to nearby Korea, Malaysia, Thailand and Taiwan for health checkups and wellness treatments, in addition to cosmetic surgery, dental treatment and elective ophthalmology or orthopaedic procedures. The relaxation of China’s one-child policy is also boosting travel for IVF, birth tourism and surrogacy, especially to Southeast Asia, the US and Canada. For private hospitals and healthcare businesses with plans to expand into China, medical tourism is an ideal first step into the market and acts as a valuable pre-cursor to direct investment. It creates a natural channel for developing an understanding of Chinese private sector patients and building relationships with business partners, all while delivering a lucrative stand-alone revenue stream. For more information, please visit: www.chinamediworld.com

Medical Device ASIA | January-February 2017 | 35


Dolomite Bio’s Single Cell RNA-Seq System accelerating cancer research

Early Diagnosis and Immediate Treatment Significantly Reduces the Risk of HIV

Hands Up for #HIV Prevention ‘Hands Up’ for #HIV Prevention is this year’s theme for the World Aids Day. Observed every year on the 1st December by World Health Organization (WHO), World Aids Day is an opportunity for people worldwide to unite in the fight against HIV, show their support for people living with HIV and to commemorate people who have died. To leverage this global movement Association of Hospital (AOH) calls on the general population to support community action to prevent HIV infection and build healthier communities as the vulnerabilities that drive the epidemic are different in different parts of the country. Globally there are an estimated 34 million people who have the virus.

Researchers at The Institute of Cancer Research (ICR), London, are taking advantage of the single cell encapsulation capabilities of Dolomite Bio’s Single Cell RNA-Seq System to investigate resistance mechanisms in prostate cancer. Karolina Nowakowska, a PhD student at The Institute of Cancer Research, explained: “Our team is focused on studying treatment resistance in prostate cancer patients, looking at the biochemical mechanisms responsible. My project is based on using single cell sequencing to help identify the specific genes which lead to treatment resistance, trying to identify biomarkers and, in the longer term, treatments which will allow a more personalized approach to therapy.” “Initially I was using FACS to perform manual sorting of cells into individual wells, but this is both time consuming and laborious, limiting me to a maximum of 20 cells per experiment. As throughput is crucial in biomarker discovery, we wanted to perform our investigations on a much larger scale and, following the publication by Macosko et al1, we decided that microfluidics was the way forward. After a demonstration of the system at Dolomite Bio’s headquarters near Cambridge, we chose the Single Cell RNA-Seq System, and can now run over 1,000 cells per experiment. Although we have only just finished optimizing our protocols, the throughput is very impressive and the system offers good reproducibility. The beauty of this technique is that it allows you to view many cellular events simultaneously and, once optimized, it’s more cost effective than manually sorting and sequencing cells.” For more information, visit www.dolomite-bio.com 36 | January-February 2017 | Medical Device ASIA

Dr. P M Bhujang - President of the Association of Hospitals said “India has shown a 66% decline in new infections since 2000, said a new UNAIDS report. Discrimination and inequality towards HIV/AIDS patients has also reduced tremendously. The quality of treatment and care provided to HIV/AIDS patients has increased a lot over the last decade. In a move to grant stronger protection to the country’s HIV community, the government also plans to introduce the HIV and AIDS (Prevention and Control) Bill in Rajya Sabha during the ongoing winter session.” By June 2016, around 18.2 million [16.1 million–19.0 million] people had access to the life-saving medicines, including 910 000 children, double the number five years earlier. If these efforts are sustained and increased, the world will be on track to achieve the target of 30 million people on treatment by 2020. Education of the community and sustainable efforts by NGO’s, charitable organizations etc. will help in creating awareness among the masses. About Association of Hospital: The Association of Hospitals has been formed under the Memorandum dated August 6, 1985 and is registered under the Societies Registration Act, 1860. The Association is also registered under Maharashtra Public Trust Act, 1950 as Public Charitable Trust with the office of Charity Commissioner, Maharashtra State. Presently there are 52 members of the Association and all of them are Public Charitable Trust Hospitals registered under Maharashtra Public Trust Act, 1950 with the concerned offices of Charity Commissioner, Maharashtra State depending upon the Jurisdiction. The members being not-for-profit charitable hospitals render yeomen service to the public and bear a major share of healthcare service to the people.


700 school students participate in FOGSI - MOGS Youth Summit to empower young girls and boys with knowledge on

Reproductive Health &Healthy Living Two-days health awareness summit organised at Sathaye college and Welingkar Institute of Management witnessed participation of over 700 students starting from 8th grade in the Youth Round-March to spread reproductive and general health awareness further empowering young girls and boys with the desired knowledge on reproductive health and healthy living.” Dr.Rishma Pai President FOGSI said that FOGSI Future initiatives are to protect the future generation and we strongly believe in reducing gender discrimination, which was conveyed through interactive and informative sessions at the summit.”

The Federation of Obstetric and Gynaecological Societies of India (FOGSI), India’s largest professional organisation representing practitioners of obstetrics and gynaecology, successfully concluded a two-day ‘FOGSI MOGS Youth Summit’, an informative and interactive programme aimed at creating awareness about reproductive health, general health and social awareness amongst the young girls and boys. The summit was organised in association with Mumbai Obstetric and Gynaecological Society (MOGS), an affiliated arm of FOGSI with 2200 doctor members and Rotary Club Mumbai Parleshwar. Ms. Ulrika Sundberg, Consul General, Swedish Embassy graced the occasion as Chief Guest at the summit organised at Sathye College and Welingkar’s Institute of Management. The programme had around 700 students starting 8th grade participating in the youth round-march, led by Dr. Jayam Kannan, VP, FOGSI. The youth round-march was flagged with torches and flags, with an objective to spread awareness on the importance of healthy diet, physiology of reproduction, building strong bones, use of contraception, prevention of sexual abuse, prevention of cervical cancer and gender sensitization. The students held placards and banners displaying messages that urged people and specifically young girls and boys to adopt healthy way of living. The program also witnessed interactive and sensitive role plays performed by young girls on saving a girl child. Also, the nursing student team of Kokilaben Dhirubhai Ambani Hospital performed a play on the plight of a sexually abused victim girl. Rtn. Smita Puranik from Rotary Club of Mumbai Parleshwar coordinated with the schools in the city for the event.

Speaking on the occasion Dr. Suchitra Pandit, Past President, FOGSI, said “India is a young country with unmet need for reproductive health education. Initiatives such as FOGSI-MOGS Youth Summit is a step towards

FOGSI-MOGS also organised health exhibits, panel discussions and health talks to educate youth on preliminary and necessary measures that one should adopt to secure a healthy life. The doctors of FOGSI and MOGS educated young girls on identifying health related problems such as reproductive, cervical cancer, anaemia, obesity; and consulted on prevention techniques and immediate action that needs to be taken at an early stage.

About FOGSI The Federation of Obstetric and Gynaecological Societies of India (FOGSI) registered and headquartered in Mumbai is the professional organization representing practitioners of obstetrics and gynaecology in India. FOGSI is probably one of the largest membership based organizations of specialized professionals with 223 member societies and over 29,310 individual members spread over the length and breadth of the country. FOGSI exists to encourage and disseminate knowledge, education and research in the field of obstetrics and gynaecology. The federation promotes preventive and therapeutic services related to the practice of obstetrics and gynaecology for betterment of the health of women and children in particular and the wellbeing of the community at large. It also advocates the cause of reproductive health and rights and to support and protect the interest of practitioners of obstetrics and gynaecology in India. The Federation also collaborates and partners with the Government of India and is an invited reprehensive on all relevant policy making bodies of the government on issues related to women’s health. FOGSI has affiliation with international and regional organizations like FIGO, AOFOG and SAFOG, with many of its members having occupied prestigious positions in these organizations from time to time. The Indian College of Obstetrics and Gynaecology is the academic wing of FOGSI with over 1010 fellows. Medical Device ASIA | January-February 2017 | 37


Fortis Hospitals Fooducated Patients, Visitors and Employees on Dietetic Week

T

o raise awareness on consumption of healthy food, Indian Dietetics Association celebrates January 10 as Dietetics Day. Supporting the initiative is Fortis Hospitals, Bannerghatta Road,which educated the employees, attendants, patients and visitors on benefits of having a healthy diet, for the week till January 18, Wednesday. The week ended with an exhibition on highlighting the importance of dietetics and nutrition in maintaining one’s health, and in the prevention and treatment of diseases. The theme this year, decided by the association, was,“Consult aDietitian and get FOODUCATED”. Ms Shalini Arvind, Chief Dietitian, Fortis Hospital, Bannerghatta Road, says that diet forms an important part of patients’ recouping process after any medical procedure they undergo. During the event, she mentioned, “There has been a huge increase in the incidence of lifestyle diseases in the last decade. Coronary artery disease (CAD), ischemic stroke, diabetes, and some specific cancers, which until recently were common only in high-income countries, are now becoming the dominant sources of morbidity and mortality worldwide (WHO 2002). Reducing the identified, modifiable dietary and lifestyle risk factor could prevent most cases of coronary artery diseases, diabetes and many cancers.” She adds, “Preventive Nutrition helps us in a long way in preventing or delaying the onset or reducing the complications of diseases. There is a 38 | January-February 2017 | Medical Device ASIA

big role for Dietitians to play in imparting and spreading the knowledge of preventive nutrition to reduce the incidences of Non-communicable diseases (NCDs). About Fortis Healthcare Limited Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka with 45 healthcare facilities (including projects under development), approximately 10,000 potential beds and over 330 diagnostic centres.


Genomic Testing to be Harnessed for Precision Medicine in Oncology and Inherited Genetic Disorders

W

ith the genomic profile of each cancer patient being unique, oncologists are faced with the challenging task of deciding a specific treatment that works best for each patient. Keeping this in mind, Strand Life Sciences, a global leader in precision medicine diagnostics, in association with Queen’s NRI Hospitalorganized a symposium on ‘Next-Generation Sequencing for Precision Medicine in Oncology and Inherited Genetic Disorders’. With advancements in genetic testing, precision medicine now offers clinicians a way to manage a patient’s treatment with targeted therapies based on each patient’s unique genetic profile.

Dr. Urvashi Bahadur, PhD Vice President – Clinical Diagnostics & Sr. Director– Medical Genetics & Genomics Strand Life Sciences, Bangalore

Cancer is among the leading causes of mortality and morbidity worldwide. According to National Institute of Cancer Prevention and Research around 2.5 million people are living with cancer in India with over 7 lakhs new cancer registered cases every year.

Delivering the keynote address at the symposium, Dr. Himabindu Gaddipati, CEO & Founder Elixsys Inc., San Diego, CA, highlighted the clinical utility and practical application of NGS. She said, “Precision medicine facilitated by genomic profiling is expected to help tailor treatment to the patient. Genetic testing has enabled us to identify individuals and families at a high risk for developing hereditary cancer, and provide them with personalized surveillance and risk-reduction measures. In addition to the field of oncology, genetic testing has immensely impacted the prenatal and neonatal diagnosis of inherited disorders. Speaking about the application

of NGS for selection of targeted therapies for treating somatic cancer, Dr. Urvashi Bahadur, Vice President – Clinical Diagnostics & Sr. Director–Medical Genetics & Genomics, Strand Life Sciences, Bangalore, said, “Next-Generation Sequencing (NGS)-based genomic tests profile for mutations within multiple genes simultaneously, eliminating the need for multiple tests, and provides a comprehensive view of genomic changes associated with cancer. It also helps oncologists to get clinically actionable and timely results to decide on treatment options for patients.” Ms. Sushma Patil, Genetic Counselor, Strand Life Sciences, Bangalore, highlighted the importance of genetic counselling and testing for hereditary cancer and inherited neurological disorders. Dr. Sudhir Borgonha, Chief Medical Officer, Strand Life Sciences, Bangalore, and Mr. Archit Sahai, Medical Science Liaison, Strand Life Sciences, Bangalore gave the opening remarks and introduced the genomics concept and precision medicine. The symposium served as an ideal platform to engage the Visakhapatnam medical fraternity in an interesting discussion about precision medicine in oncology and genetic disorders.

About Strand Life Sciences A History of Innovative Genomic Research Strand Life Sciences is a global genomic profiling company and leader in precision medicine diagnostics, aimed at empowering cancer care and genetic testing for inherited diseases. Strand works with physicians and hospitals to enable faster clinical decision support for accurate molecular diagnosis, prognosis, therapy recommendations, and clinical trials. The Strand Center for Genomics & Personalized Medicine is India’s 1st and only CAP & NABL accredited NGS laboratory. Strand’s NGS laboratory at Aurora, Colorado, USA is a CLIA accredited facility. For more information, please visit www.strandls.com Medical Device ASIA | January-February 2017 | 39


GLOBALHealthPR starts 2017 with expansion of Asia-Pacific footprint and capabilities New regional headquarters, senior appointment and Hong Kong agency partner reflect growing demand for GLOBALHealthPR’s unique independent agency network including leading the healthcare team at Fleishman-Hillard in Singapore, successfully starting his own firm focusing on the health sector, and serving as Managing Director of Ogilvy Public Relations Vietnam and CEO & Market Leader for Burson-Marsteller Korea. “The Asia Pacific region is the source of considerable growth and innovation in the healthcare industry, creating an increased need for bestin-class, health-focused strategic communications solutions for clients in the region,” said Jonathan Wilson, President of GLOBALHealthPR. “James is a proven leader with more than two decades of experience working across diverse roles and geographies in the health and life-science industries. We’re thrilled he’s chosen to join GLOBALHealthPR and believe he has the right vision and expertise to further our position as the top healthcare communications network in the region.”

GLOBALHealthPR®, the largest independent health and science communications agency partnership worldwide, has announced the opening of its new Asia-Pacific headquarters, located in Singapore’s Central Business District. The new office is opening under the direction of James Yi, the newly appointed Executive Director, APAC. It also follows the recent addition of Madison Communications as GLOBALHealthPR’s exclusive partner in Hong Kong, allowing the network to more closely support emerging client needs in the region. Asia Pacific (APAC) is an important region for GLOBALHealthPR, which boasts a global presence in more than 40 markets spanning six continents. The unique GLOBALHealthPR model, which has united a roster of best-inmarket independent agencies, is now in its 16th year of operation with more than a decade working in APAC. The GLOBALHealthPR network delivers local, regional and global healthcare communications expertise through carefully selected partner agencies that choose to work together based on shared values, independence, and flexibility. “GLOBALHealthPR has successfully harnessed the dedication and commitment of top independent agencies, creating a communications powerhouse with deep-rooted and focused expertise across the APAC region,” said Yi. “By aligning the strongest regional agencies, GLOBALHealthPR has created an unmatched ability to deliver health and science strategies, while remaining both nimble and aggressive in communicating with key stakeholders. I look forward to forging partnerships with our clients that go beyond the confines of a traditional holding company model.” Yi steps into his new role having spent the last 12 years based in APAC leading both regional and country-level PR programming. Overall, he has 20 years of experience in the health and communications industries, 40 | January-February 2017 | Medical Device ASIA

“This formidable step will surely help strengthen GLOBALHealthPR’s presence in the APAC region. With the rapidly changing healthcare dynamics in India and around, the core healthcare expertise that James brings to the table, will add value to our offerings and cutting edge to our services,” said Dinesh Chindarkar, Co-Founder & Director of MediaMedic Communications.

About GLOBALHealthPR® Founded in 2001 with headquarters in New York and regional hub offices in London and Singapore, GLOBALHealthPR is a partnership of independently owned and operated health and science communications agencies that choose to work together based on common values. With more than 600 health-specialist communications professionals, researchers and medical advisors on staff serving over 200 organizations globally, the agencies that make up the partnership share a belief in insights-driven strategies and a commitment to collaboration in order to provide clients the best possible counsel and execution. GLOBALHealthPR’s presence spans more than 40 countries covering Europe, North America, Latin America, the Middle East, Africa and the Asia-Pacific regions. GLOBALHealthPR clients include top global pharmaceutical companies, medical-device manufacturers, consumer goods companies and hospital organizations. For more information, visit www.globalhealthpr.com or follow us on Twitter: @GLOBALHealthPR.

About MediaMedic Communications – MediaMedic Communications Pvt. Ltd. is a specialised firm that helps build Health Brands. MediaMedic Communications provides Brand Communication, Health-PR and Digital & Social media services for its pharmaceutical, nutraceutical, diagnostic and healthcare clients. MediaMedic has experts from the field of marketing, digital, PR, medical, nutrition and creative to meet the unique needs of clients in this segment, making it a reliable partner in building health brands.


Harvard Emergency Medicine Specialist & Commissioner of Police, Navi Mumbai inaugurate Apollo Hospitals Advanced Emergency Care • Dedicated 1066 Response System • Apollo manages Acute Brain Stroke within 42 minutes, surpassing International benchmark •Launches life saver club

Apollo Hospitals, the 500-bed state-of-the art, multi-speciality tertiary care hospital in Navi Mumbai, inaugurated its Advanced Emergency Care and 1066 emergency response program at the hands of Shri Hemant Nagrale, Commissioner of Police, Navi Mumbai and Dr Thomas Burke, Emergency Medicine Specialist, Harvard University, USA. The Emergency Response System is initiated with the number ‘1066’, which is answered by trained emergency personnel who would advise and dispatch GPRS enabled ambulance. The ambulance, among the most advanced in the Mumbai, has trained paramedics with all essential equipment and drugs catered to deliver care at the bedside or on the road. Shri Hemant Nagrale, Commissioner of Police, Navi Mumbai, said, “I’m happy to inaugurate the Advanced Emergency Care Centre. This will help the emergency and critical care patients of Navi Mumbai, avail treatment within the “Golden Hour.” Also, we are happy to be associated with Apollo Hospitals for our Road Safety Week 2017 initiative and have been imparting safety and first aid training with their support.” Dr Thomas Burke, Emergency Medicine Specialist, Harvard University, USA, speaking at the launch said, “Emergency medicine has evolved over the years with new benchmarks. It is important for healthcare centers to adapt the international clinical protocols, as it helps saving time and life in crucial moments.” Dr Nitin Jagasia, Head, Emergency Medical Services, said, “There is a 2 way communication between the ambulance and the hospital to ensure specific areas such as cath lab, operating theatre, ICU’s are prepared to receive the patient. The GPRS enabled tracking provides the team at Apollo an accurate estimate of patient arrival. The Apollo emergency response protocol has ensured that the majority of emergency cases have been stabilized in a time critical manner at par with the international benchmark for golden hour management.” The Stroke Clinic is a multi-disciplinary clinic where stroke patients are assessed by doctors, specialist nurses, physio & speech therapists to formulate a comprehensive treatment plan for each patient.

Mr Ravikant (Name Changed) 64 year-old, arrived from a local nursing home via ambulance. Apollo Hospitals, Mumbai immediately identified left sided stroke, arranged for basic blood tests and a CT Angiogram which was completed in 25-30 mins. After 10 minutes of counseling with his family, thrombolysis medication was started in 42 minutes. The International standard for the same is 60 minutes. Dr Girish Nair, Consultant, Neurology, Apollo Hospitals, said, “A person suffers from a brain stroke every three seconds in India. Following the onset of blockage of blood supply to the brain, over 1.4 million nerve cells are irreversibly damaged every second. The emergency room team did a stellar job of triaging the patient, completing the critical tests including CT scan of the brain and arranging to start the treatment in a new benchmark setting time of 42 minutes. The patient received the clot busting drug which worked to open up the blocked artery and restore blood flow in the brain. Within 5 hours he had fully recovered from the paralysis and regained his ability to speak and move normally.” Dr Narendra Trivedi, CEO, Apollo

Hospitals, Navi Mumbai, said “Apollo Hospitals has always been monitoring its service delivery against international benchmarks, which demonstrates quality of our care. This does not mean how fast we deliver the treatment, but actually how appropriate the care is and Apollo has always been driven by clinical outcomes.” Apollo Hospitals, Mumbai, has also initiated the “Lifesaver’s Club”, along with the Navi Mumbai RTO / Traffic Police Road Safety Week, wherein Apollo Hospitals will deliver basic life support training across various residential societies and corporates to develop community champions who would help save lives when it matters most. About Apollo Hospitals:

Apollo Hospitals - Navi Mumbai, is a state-of-the art 500 bedded facility with 120 Critical Care Beds and one of the most advanced Multi-speciality Tertiary Care Hospitals in the region of Mumbai and Navi Mumbai. The hospital offers comprehensive and integrated super-speciality services under one roof with highly experienced doctors of national and international repute supported by a well-trained team of nurses & technicians and other support staff. The unit comprises of more than 50 specialties with accessibility to advanced technologies and clinical expertise.

Medical Device ASIA | January-February 2017 | 41


P E R S O N A L I T Y

Dimple Mirchandani Founder – Holistic Nutrition Astrology, Tarot Reading & Numerology. Recently she achieved an international certification in Yoga training & currently is pursuing Diploma in Sports Nutrition from oxford learning.

V

ery few people on this universe are honest to their inner voice, listen to their gut and do what they really enjoy. This passion for doing something close to their heart then supersedes everything and they discover a new meaning of life. The story of 25 Years old Dimple Mirchandani perfectly spells it. Having qualifications in the field of Accounting and Finance (University of Manchester, UK), being an entrepreneur - hailing from a large business family, Dimple listened to her inner voice and discovered her passion through Holistic Nutrition. Her own journey and experience inspired her to make use of her expertise for well being of others and that’s how Holistic Nutrition was conceived. She passionately believes in the healing power of nature and works with an integrative approach to healthcare which incorporates wholeness in a person’s being. Her work is about educating, guiding and empowering her clients – to tap into their own innate healing abilities & discovering foods that best work for them. As she says “body is the most precious vehicle, to enjoy our journey of life”. Dimple Mirchandani, is an Internationally Certified Nutrition And Health Consultant from Institute For Integrative Nutrition (Newyork ,USA), where she studied innovative coaching methods, practical lifestyle management techniques, and over 100 dietary theories; everything from Ayurveda, gluten-free, and Paleo, to raw, vegan, macrobiotics, and what not, with world’s top health and wellness experts like Deepak Chopra , Andrew Weil , David Katz, Mark Hyman, David Wolfe, Marian Nestle and many other researchers and nutrition authorities. She also has certification in

42 | January-February 2017 | Medical Device ASIA

Holistic nutrition emerged naturally as a part of her being - based on an individual and not on some particular theory of eating. Eating well and living a disciplined life leads her to realize her gut feeling. As she followed her instincts, it lead to the discovery of a new aspect of life that can only be experienced - as she says “Universe is magical, you just got to be observant enough to feel the magic”- she believes that universe is a vast sea in which we are immersed and from which we are formed- once we are aligned with our energy, we become more cooperative part of the ecosystem. According to her “once you start eating the food that best works for you and calm your mind and body- your body gets aligned with mind and soul”. One of her biggest notion is that “nourishing your soul is just as important as nourishing your body”- meaning eating good nutritious food will be of no good if a person is not happy. Thus, being happy in your relations and work is equally important to lead a healthy life as having a healthy relation with food. She helps people discover what way of eating and lifestyle works best for them , as no 2 individuals have the same body composition - rightfully said “one person’s food can be another person’s poison” .Dimple believes that wellness is an integrated process of physical activity, mental reflection, social engagement, and emotional awareness. Her program is a combination of personalised meal plans along with customised recipes based on individual likes and introducing functional activities with specific strengthening and flexibility exercises to achieve balanced physical function. Whether you are training for competition—or just training for life—she can get you on the right track.

Her journey of nutrition started at a very early age, the roots of which were planted by her mother who has been an inspiration behind all. Her mother being a wonderful cook, who replicated every dish in a healthy way, became the reason behind her curiosity to gain more knowledge in this field. As she says “I am just a true reflection of all that my Ma is”. Dimple‘s love for fitness started at a very young age being a natural athlete. She grew up playing basketball, badminton, skating, swimming, learning classical dance and what not. Naturally she was able to initiate and supervise brief workshops for her colleagues and friends from various countries, ages and abilities, which sparked a passion to become a Holistic Nutrition Expert. She strongly believes that Human beings have immense potential , way beyond what human mind can perceive - and people are unable to discover their potential & live to the fullest as they are too busy juggling between their self created aches , pain and chronic ailments . In that frame of mind, half of the day is spent in thinking about the problem or how to temporarily overcome it- leaving them utterly confused. So the mantra is believing in yourself and discovering what way of eating and living works best for you. There is no one way or uniform diet that is fit for all. At Holistic Nutrition, She inspires people to be more aware of their true selves, their strengths and to create their own signature lifestyle. As she says “we are all unique individuals - work of art, but are also work in progress - we must strive to be better of what we are each day”. Dimple is a nature lover and is passionate about reading & writing. She hopes to be an author someday. Her message to all “I truly wish & hope that each one of you can experience the bliss of true health & fitness – and experience LIFE in each moment of living”


IIMC 2017 – International Injection Moulding Conference in Aachen

IKV Conference on March 15 - 16, 2017 will give live demonstrations on the machines to give the delegates an insight into research at the Institute. In addition to the strategically selected topics and papers, the IIMC provides a global, inter-industry network platform for all companies active in the injection moulding segment. The accompanying trade show will also contribute to this. The conference is directed at international managers and experts from all areas of the industry as well as processors, converters, machine manufacturers and raw material suppliers.

For the third time, the Institute of Plastics Processing (IKV) in Industry and the Skilled Crafts at RWTH Aachen University has issued an invitation to attend the International Injection Moulding Conference, in short: IIMC 2017. The conference will be held in Aachen on March 15 - 16, 2017. National and international experts from the injection moulding sector will speak about innovative developments in injection moulding engineering and process technology, new approaches for enhancing production efficiency and the impact of digitisation in the context of Industry 4.0 for the plastics industry. Weight reduction in automotive applications, ambitious material demands in electronics, and stringent requirements on cleanliness in medical engineering are only some of the special challenges facing injection moulding processors. This necessarily means that the injection moulding technologies must be constantly refined and adapted. The papers to be given at the third IIMC will pick up on these challenges and discuss potential solutions and further developments. Experts from the industry will speak, for example, about optics made of plastics for innovative human-machine interfaces, the shortening of product development processes in electronics, optical lenses made of liquid silicone rubber (LSR), the manufacture of transparent composites, improving the surface aesthetics of body panels, and use of the liquid injection technique in the automotive sector. The topics will be supplemented by papers on software developments and integrative functionalisation processes. Professor Christian Hopmann, head of the Institute of Plastics Processing, will represent the scientific side, and his scientific assistants will present

papers on the importance of Industry 4.0 for the plastics segment, the integrative production of individualised lightweight parts, and the role of simulation in the processing of long fibre-reinforced thermoplastics. Another part of the program will be a visit to IKV’s injection moulding pilot plants and laboratories for composite materials. There, members of IKV

The speakers from six countries are from the following companies: Engel, Austria, LG Electronics, Korea, Microsoft Corporation, USA, Sabic, Netherlands, Sanoh, Japan, and Hella, IOS, Osram and SimpaTec from Germany. The conference will be moderated by Dipl.-Ing. Markus Lüling, chief editor of the trade magazine, K-Profi. The conference language is English. More information: www.iimc-aachen.com www.ikv-aachen.de

About IKV IKV, the Institute of Plastics Processing at RWTH Aachen University, is Europe-wide the leading research and education institute engaged in the field of plastics processing enjoying outstanding reputation. More than 300 staff are employed in finding solutions to problems connected with processing, materials technology and part design in the plastics and rubber industries. IKV’s close contacts with industry and science, together with its outstanding facilities, enable cutting-edge research in plastics technology and ensure that students benefit from a comprehensive, practically oriented course of study. Plastics engineering graduates from IKV are thus sought-after experts in industry. In organisational terms, IKV is divided up into the four specialist departments of Injection Moulding, Extrusion and Rubber Technology, Part Design and Materials Technology, and Composites and Polyurethane Technology. The institute also takes in the Centre for Analysis and Testing of Plastics, and the Training and Further Education department. IKV is run by an Association of Sponsors, which currently has a membership of more than 230 plastics companies from all over the world. Univ.-Prof. Dr.-Ing. Christian Hopmann is Head of the Institute and Managing Director of the Association of Sponsors. He also holds the Chair of Plastics Processing at the Faculty of Mechanical Engineering at RWTH Aachen University. Medical Device ASIA | January-February 2017 | 43


Ms. Kanchan Naikawadi, Founder and Director, Indus Health Plus, wins two Silver Awards in 2016 Stevie Awards for Women in Business Ms. Kanchan Naikawadi, Founder and Director, Indus Health Plus was conferred with two Silver Stevie Awards in the categories namely, ‘Female Entrepreneur of the Year in Asia, Australia or New Zealand’ and ‘Female Entrepreneur of the Year award’ in the 13th annual Stevie Awards for Women in Business recently held at New York. The Stevie Awards for Women in Business honors world’s top female entrepreneurs, executives, employees and the organizations they run. The Stevie is widely considered to be world’s premier business award. More than 1,400 nominations were submitted this year for consideration across all categories from 31 countries. Stevie Award winners were selected by more than 160 professionals worldwide who participated in the judging process. Ms. Kanchan Naikawadi, Founder and Director, Indus Health Plus said, “I am thrilled to receive this prestigious recognition in these categories. This will further boost our confidence and we would continue serving the society with innovative healthcare solutions in preventive healthcare industry. We truly believe that preventive healthcare is the way of life and we want to spread the awareness of this cause and the importance of timely health checkups to as many people as possible. As a founder and Director of Operations, Ms. Kanchan Naikawadi plays a key role in company’s operations, brand building and marketing strategies. Her mission is to make quality healthcare ‘Available, Accessible and Affordable’ to masses and wants to educate people on benefits of timely check – up which not only saves life of a person but also saves their families from mental and physical trauma and financial distress. Save the Date!

MEDICAL FAIR INDIA

6-8 April 2017, Pragati Maidan, New Delhi, India 44 | January-February 2017 | Medical Device ASIA

Suman Agarwal –Celebrity Nutritionist and Fitness Trainer involved in, it came as no surprise that Suman bagged the Best Nutritionist Award at the Vogue Beauty awards in the year 2015. Suman founded Selfcare in the year 2001 and at present runs two clinics in Mumbai and one in the city of joy Kolkata. She heads these clinics with a team of 15 Nutritionists and strength of 30 employees.

In this era of FADS and Facts one name that is being celebrated in the nutrition industry for over a decade is that of -Suman Agarwal. Suman Agarwal- a modern day woman of substance is the founder of Selfcare India. Being an entrepreneur, an author, a classical singer, a passionate dancer adds to her dynamic persona.The head start of Suman’s journey dates back in the year 2001 when she became an Oxford certified nutritionist (Certificate Course in Food and Nutrition, Oxford University, U.K (Aff)).After which she went on to become a qualified fitness trainer from the National Institute of Aerobics (Certificate Course in Fitness from NIA).Her debut as an author was with her book “The Don’t Diet Diet Cook Book”. Since then she has written two books namely, “Unjunked”- Healthy eating for weight loss and her latest book “Superkids”. Suman has been influencing the lives of over 15000 people across the globe and still counting. Her clientele include the country’s most powerful industrialists and Bollywood personalities. With her extensive work in her field she has become the Honorary Member of Rotary Mumbai Divas and also an Advisory board member of Annam- an organization that helps underprivileged children and women in Mumbai city by providing nutrition supplements. Looking at the pace at which her venture “Selfcare” is growing and different facets of lifestyle management she has been

Selfcare has to offer a vast range of services ranging from weight-loss to weight-maintenance or weight-gain, pregnancy diet to lactation, diet for senior citizens, diets for boosting immunity, post cancer treatment, hypertension, arthritis , migraine ,PCOD, endocrinal disorders, food allergies, child nutrition and so on. “You are Unique” is the belief behind each plan being offered at Selfcare. There are different packages available that are tailor made for an individual by Suman and her team.She knows that food isn’t just a mode of sustenance but also connects you culturally and socially. She understands that people who are put on very strict limited diets cannot sustain it over a longer period, because of which Selfcare does not provide diets for mere weight gain or weight loss but has a holistic approach towards client health. Selfcare takes care of you even when you are on the Go! There are plans that fit in your travel itinerary while you are away from home! Communicating, Sharing, Listening open doors that previously didn’t exist! Believing in this concept Selfcare organizes various interactive sessions in the corporate sector and schools as a health awareness initiative. The recent venture by Suman along with her daughter, Priyanka Agarwal is making Selfcare a click away! Online diet programs for over worked and busy individuals, which enables them to monitor their health from the comfort of their workplace or home. Suman has a vision to soar far and high, she knows diet beyond papers and has the holistic approach a client needs. She takes you through your very first step towards the change till you are the change.


Jaypee Hospital performs

Dual – Lobe- Liver Transplant Surgery • •

Dual – Lobe- Liver Transplant surgery involves transplant of livers from two donors The 16 hour surgery was performed on a patient weighing 130 Kg as one single donor was not sufficient to meet the requirement of his body

Team of doctors from Liver Transplant department of Noida based Jaypee Hospital has recently performed a rare liver transplant surgery, ‘Dual – Lobe- Liver Transplant’ on a 38 year old Mongolian patient. The life saving surgery took around 16 hours. In June last year the patient got to know about his liver ailment and was advised for a transplant surgery in October. He finally underwent a Dual Lobe Liver Transplant surgery at Jaypee Hospital recently. Explaining about Dual Lobe Liver Transplant surgery, Dr. Abhideep Chaudhary, Senior Liver Transplant surgeon, Jaypee Hospital said, “This is a very rare kind of surgery. In this surgery, liver from two – donors is being transplanted to one recipient. In normal cases we do not require to perform this surgery, only a part of liver from one donor is sufficient for the transplant. But in cases where the recipient is overweight or is very huge in size, liver from one donor is not sufficient enough to perform the functions of the body normally. Hence, in such cases Dual – Lobe- Liver Transplant surgery is being done.” 38 year old Purevsuren Dorj had 130 Kgs of weight and hence a liver from one donor was not sufficient for him to survive. Finally, both of his brothers aged 35 and 31 decided to donate a part of their livers to the patient and help him lead a normal healthy life. In Dual – Lobe – Liver Transplant Surgery three surgeries are being performed simultaneously and hence it involves more complexities and challenges,” Dr. Chaudhary explained. Purevsuren Dorj, the patient said, “Prior to the surgery, my life was miserable because of my liver failure. After consulting with the doctors, I was informed that I will have to undergo a liver transplant surgery, for which one of my brother agreed to donate his liver but when Dr.

Abhideep informed me that I will need two donors for my liver transplant as just a part of a liver from one donor will not be sufficient, I got really tensed as I haven’t heard of any such surgery before. But, when Dr. Chaudhary explained me how it will be done and assured me that I will be leading a normal life post surgery it boosted my confidence and gave me the courage to undergo the transplant surgery, where both my brothers donated their livers to me. All thanks to Dr. Abhideep Chaudhary who performed the surgery and my brothers who

donated their livers to me that today I am back to my normal life”. Jaypee Hospital has been able to give a new lease of life to more than 60 people through liver transplants in the last one year. The team of doctors has done many successful transplants of patients with critical medical histories, ABO incompatible liver transplant is one of them. Now, with ‘Dual – Lobe- Liver Transplant’ surgery the doctors have again proved their medical excellence in the field and have provided a new hope to the people.

About Jaypee Hospital: The Noida based Jaypee hospital spreads across 18 acres of sprawling campus. The hospital has been planned and designed as a 1200 bedded tertiary care multi-specialty facility and has commissioned 525 beds in the first phase. The Jaypee Group is committed to providing world-class healthcare supported by renowned consultants and most advanced technology. Jaypee Hospital is a super-specialty hospital with advance healthcare facilities, the latest diagnostic services, and state- of-the –art technology focused on medical specialties that meet the needs of masses. The plan, design and construction of this hospital position itself amongst very few GOLD LEED Certified hospitals building in India.

Medical Device ASIA | January-February 2017 | 45


46 | January-February 2017 | Medical Device ASIA

An international platform to drive the Digital Health Ecosystem. The Future for Health powered by MEDICA

HOW MOBILE, IOT + DATA TRANSFORM HEALTHCARE


Medical Device ASIA | January-February 2017 | 47

6 - 8 April 2017, Delhi

BE PART OF IT!

FOR HOSPITALS, HEALTH CENTRES AND CLINICS

INDIA’S NO. 1 TRADE FAIR


Inaugural InauguralLab & Lounge Lab & Lounge Inaugural Lab & Lounge

48 | January-February 2017 | Medical Device ASIA

Final version on site might look different

Final version on site might look different

Final version on site might look different

Google Genomics

Google Genomics

Google Genomics


Clin Lab India Conference 6-8 April 2017

Pragati Maidan Exhibition Center, New Delhi

CHAIR

James H. Nichols, Ph.D., DABCC, FACB

Professor of Pathology, Microbiology and Immunology Medical Director of Clinical Chemistry Medical Director, Point-of-Care Testing Vanderbilt University School of Medicine, USA

CME Credits awarded via AACC ACCENT® Program for Clinical Laboratory Professionals AGENDA We are pleased to announce the launch of the Clin Lab India Conference, which will take place concurrently with the Clin Lab India Expo. The peer-reviewed conference will be chaired by James H. Nichols, Ph.D., DABCC, FACB with the agenda organized by TriMark Conferences, an organization with decades of experience in delivering conferences related to the practice of clinical laboratory medicine. The 2017 conference, 6-7 April, will include four tracks; chemistry, point-of-care testing, molecular diagnostics and immunochemistry. The 2018 agenda will be further expanded to include haematology and microbiology. With two speaking slots to be filled, below is the list of accepted speakers and topics as of 3 January 2017 "New Strategies for Quality Control of Laboratory Testing", James H. Nichols, Professor of Pathology, Microbiology and Immunology, Medical Director of Clinical Chemistry, Medical Director, Point-of-Care Testing, Vanderbilt University School of Medicine, USA "Cardiac Markers Present and Future", Mrinalini Sanjeev Patwardhan, PhD, Mumbai, India "Challenges and Opportunities in POC testing", Abhinav Thakur, Accurex Biomedical “Journey of Clinical Laboratory Diagnostics 1966—2016”, Ajit Golwikar, MD, Pathology, Golwilkar Metropolis Health Services (India) Pvt. Ltd., Pune, Maharashtra, India “Complement and Complement Receptors in Health and Disease Based on their Therapeutic Inhibition in Inflammation”, Dr. Lalit M. Srivastava, Head of Department, Biochemistry, Sir Gangaram Hospital, New Delhi, India “Clinical Evaluation of Laboratory Tests”, Vasu Jayaram, Product Manager, Beckman Coulter India, Bangalore, Karnataka, India “Molecular Diagnostics in the Clinical Laboratory”, Pradeep Kumar Dabla, MD, Associate Professor, G B Pant Institute of Postgraduate Medical Education & Research, New Delhi, India “Point of Care Diagnostic Testing World Markets”, Samuel Rjin, Mumbai, India "Pre-analytical errors in a Clinical Laboratory Setup", Dr. R. Selvakumar, Senior Consultant, Jeev Diagnostics Pvt. Ltd. (Title TBA) Dr. Saantwana Vernekar, Head (West SBU)- Quality Assurance, Metropolis Healthcare, New Delhi (Title TBA) Dr. Praveen Sharma, Professor and Head, Biochemistry at All India Institute of Medical Sciences, Jodhpur (Title TBA) Dr. Anil Handoo, Head, Department of Laboratory Services, BLK Super Specialty Hospital, New Delhi


Farah Khan leads the talk on infertility with Merck’s ‘Parents of Fertility’ initiative - Launches a video sharing her journey to parenthood with IVF - Encourages couples who are unable to conceive to seek specialized treatment Farah Khan, ace director, actor and choreographer in association with

Today, despite rapid advances in treatment, infertility affects nearly

Merck, pioneers and world leaders in Fertility recently

10-15% of married couples in India, nearly 27.5 million couples. It is

released a video on infertility. The video, a personal

estimated that while female factor accounts for 40-50% of infertility

memoir of Farah’s journey to parenthood is a vivid

among couples, infertility attributable to male factors is on the rise and

recollection of her fears, challenges, doubts and

constitutes 30-40% of infertility1. Several factors including changes

ultimately her story of hope, belief and positivity

in lifestyle, stress, job pressure, galloping urbanisation, obesity, rising

towards IVF that led her to become a mother.

levels of tobacco and alcohol consumption, the

Merck released this video as part of their ‘Parents

recent trend of late marriages and lack

of Fertility’ awareness initiative that helps and

of awareness about timely diagnosis and

supports couples in India through this journey

treatment contribute to infertility1,2. The

of parenthood.

still prevalent stigma around IVF in India and the conservative backdrop linking

Talking about her experience of going through

social and religious concerns also pose

IVF, Farah Khan said, “IVF is a blessing and I

as a hurdle for people seeking IVF

am really thankful as it has changed my life.

treatment3.

A lot of factors today make it difficult for some couples to conceive; but we have solutions in

References:

the form of treatments. And I strongly believe

1. Call for Action: Expanding IVF treatment in India-EY

in IVF, it helped me conceive my angels. Being

2. Reprod Biol Endocrinol. 2013; 11: 66.

persistent, positive and patient towards the

3. Facts Views Vis Obgyn. 2010; 2(2): 131–138.

procedure paid off. And if IVF can change my life, it could change yours too.”

About Parents of Fertility:

Farah and her husband Shirish tried for two years for a baby but were

Merck’s ‘Parents of Fertility’ is an awareness initiative, a global leader in fertility medicine, to support couples in India in fulfilling their dream of parenthood. It provides information on infertility in a simple, user-friendly manner for couples seeking help.

unable to conceive naturally. However, with the help of Fertility specialists, at the age of 43, they were able to become parents giving birth to daughters Diva, Anya & son Czar safely through IVF. Since then she has been very vocal about the treatment being a fantastic option for those who have not been able to conceive. The video is a medium through which Farah Khan and Merck have come together to drive awareness around infertility. Speaking about the campaign, Anand Nambiar, Managing Director, Merck India said, “We are happy to share that our awareness efforts now have a new face and voice with Actor, Director & Choreographer Farah Khan, coming on board as a Cause Ambassador for our ‘Parents of Fertility’ digital awareness initiative. Merck has taken many small steps over the years to spread awareness on infertility as we understand that seeking treatment is emotionally & physically challenging. With this video we expect to reach out to millions of couples seeking help with the message that infertility can be dealt with and one should not lose hope and seek help of specialists to fulfil their dream.” 50 | January-February 2017 | Medical Device ASIA

‘Parents of Fertility’ has also listed clinics that specialize in IVF treatment in India to help couples get closer to seeking the right guidance and expertise. Having a child is every person’s right, and with advances in IVF treatment, many couples have been able to fulfil their dream of parenthood. We believe that you too can fulfil this dream by hoping again and seeking treatment of a fertility expert. Visit www.parentsoffertility.com and learn how infertility can be dealt with. About Merck Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cuttingedge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.


Trump’s decision on Global Gag Rule a blow to women in India

Cataract affecting at early age: 25% Patients below 50 years Earlier Diabetes Infliction the main cause: Dr. Mehta, The Vission Eye Center

More than 5 million women in India this year will have an unsafe abortion because they lack access to safe, high-quality abortion care. These are women who want to avoid pregnancy but lack knowledge, agency and access to modern contraception and/or abortion. Death from unsafe abortions continue to be the third largest reason for maternal deaths in the country. Additionally many young girls and women risk serious injury undergoing a backstreet abortion process. President Donald Trump’s decision to reinstate the Global Gag rule Global Gag Rule, a harmful anti-choice and anti-reproductive rights policy has huge implications on women’s health worldwide, including in India. The policy forces organizations to choose between receiving U.S. foreign assistance funds and providing comprehensive—often lifesaving—care. The policy restricts organizations that receive U.S. family planning funds from using private funds to inform or educate their government on safe abortion or to provide legal abortion services. Lack of access to contraception and safe abortion is a major public health crisis for women in the world’s poorest countries. But rather than addressing this crisis, the Global Gag Rule broadens restrictions already imposed by the Helms Amendment, which prohibits the use of U.S. funds for abortion-related work overseas. I believe this political move will endanger the lives and health of the poorest and most vulnerable women in our country by denying access and putting them at risk of unsafe abortion, says Mr. Vinoj Manning, Executive Director, Ipas Development Foundation (IDF), an NGO that works across the country with the objective of ensuring access to comprehensive abortion care for women in India. This decision shall result in immediate withdrawal of millions of dollars aid committed for contraceptive access as well as comprehensive abortion care globally and it will have an impact on India too. While there is a global movement to invest in women’s rights and autonomy and their health, to prevent this move from being a real setback, this is the time for other bilateral agencies, private foundations and corporates to step-up and bridge the gap. “I believe that Mr Trump’s decision is another unfortunate instance of bad politics and personal prejudice trumping women’s reproductive rights.” 52 | January-February 2017 | Medical Device ASIA

Cataracts are often associated with senior citizens, however, every year there have been growing number cases of it affecting more number of younger people as well. Eminent eye surgeon Dr. Himanshu Mehta, a senior doctor at The Vission Eye Center whose patients include celebrities, CXOs and HNIs, has seen the average age of cataract patients dip, creating new challenges and also giving rise to modern treatment lines. Cataract is clouding of the natural lens in the eye leading to decrease in vision usually associated with aging. However, there have been cases of patients much younger than their 50s and below who are developing cataracts. According to data compiled by The Vission Eye Center, around 25% patients have developed cataracts below 50 years – an age which is considered too young for cataract. “Cataract, which used to be an old person’s disease, is now common at ages below 50. Modern lifestyles, food choices, sedentary lifestyles and lack of exercise are leading to earlier Diabetes and this is the most significant factor that has caused this demographic shift. Early detection and treatment is therefore an imperative, especially with the modern lines of treatment available. Patients now are afflicted with cataract in their productive years and to have an uninterrupted work life, it is imperative that they get it detected and treated as soon as they see symptoms”, said Dr. Mehta. “There are several environmental factors also that may explain the lowering age shift for cataract. Ubiquitous usage of cell phones, computers and tablets over recent years has also contributed to cataract afflicting younger age groups. Additionally, the shift of the eye ailment to younger age is also related to improved detection methods. Decades ago, when the surgery was not precise, patients were advised to wait till the vision is severely affected. But today, it is unacceptable for the younger working people or elderly to live with poor vision when the surgeries are now quicker and safer”, he added. Modern cataract technologies like FLACS (Femto Laser Assisted Cataract Surgery) have automated some of the most critical steps in cataract surgery making it safer, more precise and reproducible than they were a generation ago. “We have the most advanced technologies in treating cataracts available here in India today called FLACS. Lensx is one such system available with many Eye Surgeons here in our country and going more wide spread all across. The bottom-line is that newer medical technologies are now available to treat cataract better and faster than ever before”, said Dr. Mehta. About The Vission Eye Center Vission Eye Center’s commitment to clinical excellence is lead by over 15,000 refractive and 30,000 cataract treatments. The hospital’s team of specialist eye surgeons and ophthalmic doctors are qualified medical practitioners who have specialized in Ophthalmology, with many continuing to work in other fields of eye surgery. One of the leading eye surgeons in Mumbai, Dr. Himanshu Mehta has provided hope and clear vision to many of his patients. In Mumbai, he has also proven to be eye surgeon of choice to big names in the industry.


Unique Group brings expertise in hyperbaric oxygen treatment chambers to new healthcare markets About Unique Group Unique Group - Founded in 1993, Unique Group is among the world’s prominent integrated subsea and offshore solution providers. Through its six operational business divisions, Unique is a specialist in the provision of engineering, sales and rental of equipment for the marine, diving, and subsea market sectors. The group has an established manufacturing capability for the delivery of customized engineering projects worldwide. Unique is headquartered in Sharjah, Middle East and has local presence in the USA, UK, South Africa, India, Singapore, Rotterdam in the Netherlands, and employs over 500 people worldwide.

Unique Group, the leading integrated subsea and offshore solution provider, is investing almost 2m euros in an innovative healthcare division to bring its 25 years’ of expertise in hyperbaric oxygen treatment (HBOT) chambers to new markets. The new division – Unique Medical Technology – will launch in February 2017 at the Arab Health Show in Dubai, where the business will be demonstrating its expertise in quality focused production and client services for the healthcare sector. The move follows the acquisition in 2015 by Unique Group of Oceanwide SaS, the Netherlands-based market leader in the design, construction and maintenance of self-propelled hyperbaric lifeboats. Headquartered in Rotterdam, Unique Medical Technology will serve the healthcare market across Europe, Middle East and Asia and draw on the experience, knowledge and expertise of the wider Unique Group. Harry Gandhi, chief executive of Unique Group, comments: “This significant investment in our new division draws on nearly three decades of engineering expertise in the maritime industry to bring market-leading hyperbaric chambers and client services to the healthcare sector. “There has long been a gap for a genuine hyperbaric specialist company in the medical sector and Unique Medical Technology will fill that space. We are already processing enquiries for our products and we will be working 54 | January-February 2017 | Medical Device ASIA

initially with hospitals and clinics from our base in the Netherlands. Over the coming years we will use our engineering expertise for further product development within this important sector. ” The new business will initially focus on the production of hyperbaric oxygen treatment (HBOT) chambers with integrated critical care monitoring equipment and will also provide specialist training in the use of the technology. With a focus on efficiency and quality, the chambers will be produced within 3 to 6 months, depending on specification. Flexible finance offerings will also be available. Traditionally used in the diving industry, HBOT chambers are now used in the medical sector for treating various conditions, such as carbon monoxide poisoning, Diabetic wound care and nonhealing cuts.

Unique Group is the largest supplier of diving life support equipment in the world, with a long and successful track record of developing hyperbaric chambers and their constituent parts for the subsea and offshore industries. Unique Medical Technology’s hyperbaric oxygen treatment chambers are designed and manufactured by world-class engineers. The chambers comply with stringent design codes for medical devices (as per EC9342) and the key features of the standard chamber include ·

diameter/length of 2200mm/6.2m · capacity for 10 people in the main chamber and two in the entrance chamber · working pressure for HBO chamber is min 1.8 up to max 2.8 bar · digital chamber control system · specially-designed compression cooling control system · ‘whole room’ or individual seat entertainment, with full selection and control systems. Chambers can also be built specifically to clients’ requirements.


Source for the latest high-end manufacturing products / solutions from 400 global solution providers Network with 12,500 trade professionals Keep updated with emerging technologies such as additive manufacturing (3D Printing) and robotics solutions Explore new possibilities at the Capabilities Hub, Optics & Photonics Innovation Hub and Semiconductor Innovation Centre Gain knowledge on IoT in aerospace, inventory & supply chain development in MRO and success stories from aerospace manufacturing at SG Aerospace Connect Discover more about Industry 4.0, automation & additive manufacturing at the Smart Manufacturing Asia conference

Pre-register your visit now at www.mta-asia.com Held Alongside

Incorporating

Organised by

Worldwide Associate Tel : +65 6233 6638 Fax : +65 6233 6633 Email : mta@sesallworld.com

MTA17VPAdMDA_W210xH280mm_D1.indd 1

Endorsed

Supported by

Held in

Tel : +44 207 840 2134 Fax : +44 207 840 2119 Email : mta@oesallworld.com

16/11/16 9:54 AM


Government of India, Registrar of Newspapers of India (RNI)#: DELENG/2009/30008

Medical Device ASIA, January-February 2017  
Read more
Read more
Similar to
Popular now
Just for you